



**Vaccines and Global Health: The Week in Review**  
**30 April 2022 :: Issue 655**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS  
Editor and  
Executive Director  
Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).

***Support this knowledge-sharing service:*** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

***Contents [click to move among sections]***

- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)



## Measles

### **UNICEF and WHO warn of 'perfect storm' of conditions for measles outbreaks, affecting children**

*Reported worldwide measles cases increased by 79 per cent in the first two months of 2022, compared to the same period in 2021, as WHO and UNICEF warn conditions ripe for serious outbreaks of vaccine-preventable illnesses*

NEW YORK/ GENEVA, 27 April 2022 – An increase in measles cases in January and February 2022 is a worrying sign of a heightened risk for the spread of vaccine-preventable diseases and could trigger larger outbreaks, particularly of measles affecting millions of children in 2022, warn WHO and UNICEF.

**Pandemic-related disruptions, increasing inequalities in access to vaccines, and the diversion of resources from routine immunization are leaving too many children without protection against measles and other vaccine-preventable diseases.**

The risk for large outbreaks has increased as communities relax social distancing practices and other preventive measures for COVID-19 implemented during the height of the pandemic. In addition, with millions of people being displaced due to conflicts and crises including in Ukraine, Ethiopia, Somalia and Afghanistan, disruptions in routine immunization and COVID-19 vaccination services, lack of clean water and sanitation, and overcrowding increase the risk of vaccine-preventable disease outbreaks.

**Almost 17,338 measles cases were reported worldwide in January and February 2022, compared to 9,665 during the first two months of 2021.** As measles is very contagious, cases tend to show up quickly when vaccination levels decline. The agencies are concerned that outbreaks of measles could also forewarn outbreaks of other diseases that do not spread as rapidly...

**In 2020, 23 million children missed out on basic childhood vaccines through routine health services, the highest number since 2009 and 3.7 million more than in 2019...**

...As countries work to respond to outbreaks of measles and other vaccine-preventable diseases, and recover lost ground, UNICEF and WHO, along with partners such as Gavi, the Vaccine Alliance, the partners of the Measles & Rubella Initiative (M&RI), Bill & Melinda Gates Foundation, and others are supporting efforts to strengthen immunization systems by:

- **Restoring services and vaccination campaigns so countries can safely deliver routine immunization programmes to fill the gaps left by the backsliding;**
- Helping health workers and community leaders communicate actively with caregivers to explain the importance of vaccinations;
- **Rectifying gaps in immunization coverage, including identifying communities and people who have been missed during the pandemic;**
- Ensuring that COVID-19 vaccine delivery is independently financed and well-integrated into overall planning for immunization services so that it is not carried out at the cost of childhood and other vaccination services;
- Implementing country plans to prevent and respond to outbreaks of vaccine-preventable diseases and strengthening immunization systems as part of COVID-19 recovery efforts.

Top 5 countries with  
reported measles cases in  
the last 12 months, until  
April 2022 [1]

Country	Reported Measles cases	Rate per million cases	First dose measles coverage (%), 2019[2]	First dose measles coverage (%), 2020[3]
Somalia	9,068	554	46	46
Yemen	3,629	119	67	68
Afghanistan	3,628	91	64	66
Nigeria	12341	58	54	54
Ethiopia	3039	26	60	58

=====

=====

## PAHO

### 1 in 4 children in Latin America and the Caribbean are exposed to diseases that can be prevented with vaccines

PANAMÁ CITY, 25 April 2022 – **In five years, the complete vaccination schedule for diphtheria, tetanus and pertussis (DTP3) in Latin America and the Caribbean has dropped from 90 percent in 2015 to 76 percent in 2020**, according to data from the Pan American Health Organization (PAHO) and UNICEF. This means that one in four children in the region has not received the full routine vaccination schedule that would protect them from multiple diseases.

The decrease in vaccination coverage precedes the pandemic; but the cessation or irregular programming of many primary health care services during the pandemic and people's fear of catching COVID19 during visits to health centers is leaving many children without vaccines.

**"The decline in vaccination rates in the region is alarming and puts millions of children and adolescents at risk of dangerous diseases that could be prevented,"** said Jean Gough, UNICEF Regional Director for Latin America and Caribbean. "The solution, and it has been proven to be effective: stronger vaccination programmes."

**The 14 percentage point drop in vaccine coverage leaves nearly 2.5 million children without the complete DTP vaccination schedule and they are at risk of dangerous**

**preventable diseases. Of them, 1.5 million are “zero doses”: they have not even received the first dose of that vaccine.**

#### ***Dangerous setback***

The decrease in coverage exposes more children to the resurgence of preventable diseases and epidemiological outbreaks have already occurred. In example, while in 2013 only 5 people in the region got diphtheria, in 2018 almost 900 cases were registered, according to PAHO data. Measles sets higher alarms because it is caused by a highly contagious virus: in 2013 there were almost 500 cases; but in 2019, more than 23,000 people got the disease.

**"As countries recover from the pandemic, immediate actions are needed to prevent coverage rates from further dropping, because the re-emergence of disease outbreaks poses a serious risk to all of society,"** Gough said. "This is an opportunity to restructure primary health care and reinforce the comprehensive and community approach that bring vaccines to the most vulnerable populations. We cannot lose the efforts of past decades and let dangerous diseases threaten the lives of children."

**UNICEF calls on the governments of Latin America and the Caribbean to urgently re-establish and strengthen routine immunization programs,** develop campaigns to increase vaccine confidence and implement plans to reach all children and adolescents and their families; especially to the most vulnerable who do not have access to health services, due to their geographic location, migratory status or ethnic identity.

:::::::  
::::::

#### **Keynote Address: Breaking the Cycle of Neglect and Panic**

Date: April 27, 2022 Type: Speeches and Transcripts



THE GOVERNMENT OF JAPAN



Australian Government  
Department of Foreign Affairs and Trade



Federal Ministry  
for Economic Cooperation  
and Development

We are meeting to discuss the issues of preparedness and response after more than two years of a global Pandemic. Although the situation has improved, we still need to be cautious given the case numbers in some countries and the low level of vaccination in some parts of the World.

The past two years have brought a lot of hardship: in terms lives lost, impacts on livelihoods and economic opportunities, and the impact on Human Capital through school closures and basic health services. This has further raised concerns about the state of preparedness of the world, and our collective ability to break the cycle of Panic and Neglect.

This is more urgent given what we know about the state of the world. In 2021, **the Global Health Security Index showed the extent of the challenge with 70% of countries showed insufficient capacity to respond to health emergencies and deliver essential health services in clinics, hospitals, and community health centers**. The pandemic revealed stark disparities in the capacity of countries to prevent and respond to COVID-19 bringing into sharp focus significant under-investments in pandemic preparedness which has amplified inequalities at all levels and highlighted the urgent need for collective action.

**A recent Bank paper shows that most low- and middle-income countries are already facing tremendous fiscal pressures from the ongoing pandemic and will not be able to mobilize the huge sums necessary for investing in preparedness nor for strengthening their health systems.**

To respond to these challenges the global community has shown a strong willingness to lean forward.

Indeed, the **IDA20** replenishment, which was hosted by Japan, has culminated in a package which includes ambitious commitments to support countries to strengthen pandemic preparedness and response. The preparedness agenda is front and center of this IDA round.

The G20 and G7 have recently endorsed a new **Financial Intermediary Fund (FIF)** to strengthen preparedness and response. The FIF is meant to complement the current offerings and close remaining gaps in support of countries around the world.

Furthermore, there is broader and growing awareness of the **One Health** approach, which offers a framework to think about prevention and preparedness at country level. For instance, this is something that we are reflecting more and more in our World Bank portfolio through entry-points in the agriculture and environment sectors.

All of these efforts have to build on what we know works, and complement it in order to provide needed resources to countries who will have to address many gaps with limited fiscal space and competing needs. This requires collaboration and strong partnerships amongst all of us. No single actor or plan can do it alone.

**This is where the Health Emergency Preparedness and Response Program is comes with its mission to catalyze, complement and connect.** It has a critical role to play in the network of services and support we are building for our clients. I want here to thank Japan, Australia and Germany for their financing for and partnership in the HEPR program...

...Today's session provides a valuable forum to delve deeper into the progress made through the HEPR Program funded efforts since the it was approved 18 months ago and the work ahead. It also affords an important opportunity to hear from leaders on the frontlines in countries and communities – essential voices from whom we must all learn as we chart the way forward.

Before I hand over to the team, I would like to leave with two thoughts:

**:: First, we need to make strong analytical work at country and global levels a priority.**

Indeed, key indicators and analysis, as well as in depth work to understand country context will be important to guide policy and investments, but also raise the awareness on what is needed.

**:: Second, although there is a momentum now around the agenda of preparedness, this can be sidelined very quickly by other emerging priorities.** I count on all partners here to help make sure we maintain the push, and that we all advocate for preparedness to be streamlined throughout all aspects of the recovery.

I look forward to listening to our many partners and friends gathered here today for this event, from the Ministers of Health of Eswatini, Guyana, Togo, and partners from Japan, Australia, WHO and the Africa Center of Excellence for Genomics of Infectious Diseases.

:::::  
:::::

### **COVID Vaccines - Humanitarian Buffer(HB)**

#### **"Broken" humanitarian COVID-19 vaccine system delays vaccinations - MSF**

*MSF Press Release 27 Apr 2022*

- People in parts of northern Syria faced delays to receiving COVID-19 vaccinations earlier this year due to an unwieldy humanitarian vaccination system.
- The COVAX mechanism is failing the people it is meant to serve due to opaque legal frameworks and unfair liability demands.
- MSF urges the COVAX partners – who include WHO, UNICEF and Gavi – to immediately fix the system and enable people timely access to vaccines.

**The COVID-19 vaccine Humanitarian Buffer(HB) is failing its mission to support people hit by the pandemic and struggling to access immunisation, says Médecins Sans Frontières (MSF).** The HB is part of the COVAX mechanism\*, whose aim is to assist groups of people who do not have access to COVID-19 vaccination in situations of humanitarian emergency. However, MSF's recent experience in northern Syria has highlighted the system's limitations and ultimate failure to fulfil its purpose.

In late 2021, when the Delta variant was still predominant, MSF teams observed a significant increase in the number of reported COVID-19 cases in Tell Abyad and Ras Al-Ain. The area, currently under Turkish control, is home to approximately 156,000 people, including almost 70,000 people in need according to the United Nations. Due to its status, the area is not included neither in the UN's cross-border mechanism for the delivery of humanitarian aid, nor covered by the Syrian government's national immunisation roll-out plan.

In November of the same year, MSF submitted an application to the UN-led humanitarian emergency COVID-19 vaccine reserve with a view to launching an immunisation campaign in collaboration with our

Syrian NGO partner, Al Ameen. However, once the application was approved approximately six weeks after its submission, **MSF was confronted with an opaque, unwieldy legal framework placing an excessive liability on field-based humanitarian organisations carrying out the operations. This led to months of consuming contractual wrangling, until the Turkish authorities made alternative plans** and the window closed on the opportunity for MSF and Al Ameen to run the planned immunisation campaign.

**"For this system to work and allow for a timely intervention, it has to be practical and fair for all partners,"** says Sarah Chateau, MSF's Programme Manager for Syria. "When we started discussing with the rest of the COVAX partners, we realised it was definitely not the case."

"To start with, we were denied access to some of the legal documents framing the procurement, which were necessary for us to assess the risks we were asked to accept," explains Chateau.

**Another significant obstacle was the deeply unbalanced distribution of liabilities in the initial version of the agreement framing the supply of the vaccines, which led to months of negotiations. In those agreements, UNICEF, Gavi (the global vaccine alliance) and the vaccine manufacturer transferred to MSF part of their liability for their own roles and responsibilities in the HB, requesting MSF to waive some of our legal avenues against them and, in some cases, indemnify them against their loss and third-party claims.** Adding to this, the sheer number of contracts and interlocutors results in a lack of overall accountability for the overall functioning of the system.

**As of March 2022, 2.5 million doses have been approved through the humanitarian buffer according to publicly available information and while more applications are in process, this is a small fraction of the 155 million doses announced at the beginning of 2022 as the HB target.**

"The Humanitarian Buffer can potentially support millions of people, particularly among hard-to-reach groups of people," says Chateau. "For the sake of our collective pandemic preparedness, **we urge the COVAX partners to work to improve the system: unacceptably lengthy negotiations, excessive contractual complexity, lack of transparency and the unbalanced distribution of liabilities are issues that need an urgent solution."**

"We appreciate the concept of the HB," says Chateau. "But the system today is failing its purpose and, more importantly, the people it is meant to serve."

:::::  
:::::  
:::::

### **Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### ***Weekly Epidemiological and Operational updates***

*Last update: 29 Apr 2022*

**Confirmed cases ::**

510 270 667

**Confirmed deaths ::** 6 233 526  
**Vaccine doses administered:** 11 438 720 838

::::::

### Weekly epidemiological update on COVID-19 - 27 April 2022

#### *Overview*


Globally, the number of new COVID-19 cases and deaths has continued to decline since the end of March 2022.

During the week of 18 through 24 April 2022, over 4.5 million cases and over 15 000 deaths were reported, decreases of 21% and 20% respectively, as compared to the previous week. However, an increase in the number of new weekly cases was reported from the Regions of the Americas (+9%) and the African Region (+32%), and the number of new weekly deaths increased in the South-East Asia Region (+41%), due to a delay in reporting of deaths from India, and in the Africa Region (+110%).

As of 24 April 2022, over 500 million confirmed cases and over six million deaths have been reported globally.

In this edition, we provide an update on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the prevalence and summary of current evidence of the Omicron variant. We also provide updates on vaccine effectiveness for the Delta and Omicron variants.

**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 24 April 2022\*\***



::::::

::::::

### Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022

*[New additions; Full scale view available at title link above]*

*[Updated on 30 Apr 2022]*

::::::

## **COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements**

*[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]*

### **AstraZeneca**

**Press Releases** - *No new digest announcements identified*

### **Bharat Biotech**

**Press Releases**

#### **[Apr 26: COVAXIN® for Children: India approves COVAXIN® in Children 6-12 years](#)**

- COVAXIN is the one of the first COVID-19 vaccines in the world to generate data in 2-18 year age group.
- COVAXIN was earlier approved for children 12-18 years of age.
- Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, welltolerated, and immunogenic in paediatric subjects in phase II/III study in children 2-18 years of age.
- Neutralizing antibodies in children were 1.7 times higher than in adults.
- No serious adverse event was reported. Pain at the injection site was the most commonly reported adverse event. No cases of myocarditis or blood clots were reported, as is to be expected with inactivated vaccines.
- COVAXIN exhibits robust immune responses in children with 2 doses and 6 months follow up, indicating durability of immune responses. Data was presented to the CDSCO Subject Expert Committee and will be published in the weeks to come.

Hyderabad, April 26, 2022: Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that BBV152 (COVAXIN ·), its whole-virion inactivated COVID-19 vaccine candidate, has received emergency use approval in children 6-12 years of age...

### **BioCubaFarma – Cuba**

**Últimas Noticias** - *Website not leading at inquiry*

### **Biological E**

**News** -

#### **[BE's CORBEVAXTM Gets DCGI Nod for Emergency Use in 5-12 Years](#)**

:: The approval comes soon after CORBEVAXTM was given the nod for 12-15-year group

:: As part of its Phase 2/3 clinical trials in 312 children aged between 5 and 12 years, Biological E administered two doses of 0.5 ml each of CORBEVAXTM or Placebo in 28 days' gap

- April 26, 2022

### **Biontech**

**Press Releases**

#### **[Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age](#)**

26 April 2022

### **CanSinoBIO**

**News** - *Website not responding at inquiry*

**CIGB**

Latest News - No new digest announcements identified

**Cinagen**

Recent News

**[Researchers announced safety and effectiveness of ReciGen \(interferon beta-1a 44 mcg manufactured by CinnaGen Co.\) on COVID-19 patients](#)**

20 June 2020

**Clover Biopharmaceuticals - China**

News - No new digest announcements identified

**Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified

**Gamaleya National Center**

Latest News and Events - See Russia below.

**IMBCAMS, China**

Home - Website not responding at inquiry

**Janssen/JNJ**

Press Releases - No new digest announcements identified

**Medicago**

Media - No new digest announcements identified

**Moderna**

Press Releases

29 April, 2022

**[Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union](#)**

29 April, 2022

**[Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada](#)**

:: Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually

:: The ten-year strategic partnership is expected to provide Canadians with rapid response capabilities to ensure future pandemic readiness

28 April, 2022

**[Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age](#)**

**Nanogen**

News - No new digest announcements identified

**Novavax**

Press Releases

Apr 29, 2022

**FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine**

*NVX-CoV2373 would be the first protein-based COVID-19 vaccine to be reviewed by VRBPAC in the U.S.*

GAITHERSBURG, Md., April 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review NVX-CoV2373 COVID-19 Vaccine (recombinant, adjuvanted) for active immunization against SARS-CoV-2 at a meeting scheduled for June 7, 2022..

**Pfizer**

Recent Press Releases

April 29, 2022

**Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use**

04.26.2022

**Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age**

04.26.2022

**Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate****R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

**Sanofi Pasteur**

Press Releases - *No new digest announcements identified*

**Serum Institute of India**

NEWS & ANNOUNCEMENTS - *No new digest announcements identified*

**Shifa Pharmed [Iran]**

<http://shafapharmed.com/>

*No news page identified.*

**Sinopharm/WIBPBIBP**

News - *No new digest announcements identified*

**Sinovac**

Press Releases

**[China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial](#)**

2022/04/26

**Vector State Research Centre of Virology and Biotechnology**

Home - No new digest announcements identified

**WestVac Biopharma**

Media - No new digest announcements identified

**Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

\*\*\*\*\*

**GSK**

Press releases for media

29 April 2022

**[SK bioscience and GSK's adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYcovione™\(GBP510/GSK adjuvant\) in South Korea](#)**

**Merck**

News releases - No new digest announcements identified

**Novartis**

News - No new digest announcements identified

**SK Biosciences**

Press Releases

**[SK bioscience and GSK's Adjuvanted COVID-19 Vaccine Candidate Meets Coprimary Objectives in a Phase III Study; Biologics License Application Submitted for SKYcovione™\(GBP510/GSK adjuvant\) in South Korea](#)**

2022.04.29

**[SK bioscience Reports Positive Phase III Immunogenicity Results of Its Adjuvanted Covid-19 Vaccine Clinical Trial of COVID-19 Vaccine, AS03-adjuvanted](#)**

2022.04.25

**Valneva**

Press Releases

April 26, 2022

**[Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate](#)**

April 26, 2022

**[Valneva Provides Regulatory Update on its inactivated COVID-19 Vaccine Candidate](#)**



## UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 30 Apr 2022


An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]



## COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

**Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)**



The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as


such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.



## Global Dashboard on COVID-19 Vaccine Equity


The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 30 Apr 2022]: <https://data.undp.org/vaccine-equity/>  
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



## Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>





## Duke – Launch and Scale Speedometer

### The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)


[See our COVID Vaccine Donations & Exports research](#)

#### Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.

Country Category:  
Top 10 Donating Countries



Data updated on Apr 28th 2022



## COVID Vaccines – OCHA:: HDX

### [COVID-19 Data Explorer: Global Humanitarian Operations](#)

#### *COVID-19 Vaccine Roll-out*

**30 Apr 2022** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 510M total confirmed cases; 6.2M total confirmed deaths**

**Global vaccines administered: 11.6B**

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 290M

Other Delivered (Number of Doses): 300M

Total Delivered (Number of Doses): 590M

Total Administered (Number of Doses): 380M




### **Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.



Website accessed **30 Apr 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



## Our World in Data

### Coronavirus (COVID-19) Vaccinations [Accessed 30 Apr 2022]

- :: [65.4%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- :: [11.59 billion doses](#) have been administered globally, and [10.09 million](#) are now administered each day.
- :: Only [15.7%](#) of people in low-income countries have received at least one dose.



:::::  
:::::

## **U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **HHS**

#### News

*No new digest content identified.*

#### **BARDA-ASPR – U.S. Department of HHS [to 30 Apr 2022]**

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

#### News

#### **ASPR funding expands manufacturing capacity for prefilled injectors to administer vaccines, medicines**

Thursday, April 21, 2022

:::::

### **FDA**

#### Press Announcements

#### **April 25, 2022 - Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children**

Today, the U.S. Food and Drug Administration expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older weighing at least 3 kilograms (about 7 pounds) with positive results of direct SARS-CoV-2 viral testing, who are:

:: Hospitalized, or

:: Not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.

This action makes Veklury the first approved COVID-19 treatment for children less than 12 years of age. As a result of today's approval action, the agency also revoked the emergency use authorization for Veklury that previously covered this pediatric population...

#### *Regulatory Actions*

#### **Vaccines and Related Biological Products Advisory Committee- FDA**

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

#### Calendar

#### **April 29, 2022 - Coronavirus (COVID-19) Update: FDA Announces Tentative Advisory Committee Meeting Schedule Regarding COVID- 19 Vaccines**

Today, the U.S. Food and Drug Administration is announcing its plans to hold virtual meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) in anticipation of complete submissions of emergency use authorization (EUA) requests in the coming months that have been publicly announced by COVID-19 vaccine manufacturers.

It is important to note that the dates below are tentative as none of the submissions are complete. The agency understands the urgency to authorize a vaccine for age groups who are not currently eligible for vaccination and will work diligently to complete our evaluation of the data. Should any of the

submissions be completed in a timely manner and the data support a clear path forward following our evaluation, the FDA will act quickly and anticipates convening the following VRBPAC meetings:

On June 7, FDA intends to convene VRBPAC to discuss an EUA request for a COVID-19 vaccine manufactured by Novavax to prevent COVID-19 in individuals 18 years of age and older.

**On June 8, 21 and 22, the FDA has held dates for the VRBPAC to meet to discuss updates to the Moderna and Pfizer-BioNTech EUAs for their COVID-19 vaccines to include younger populations.** As the sponsors complete their submissions and the FDA reviews that data and information, it will provide additional details on scheduling of the VRBPAC meetings to discuss each EUA request.

**On June 28, the FDA plans to convene the VRBPAC to discuss whether the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified, and if so, which strain(s) should be selected for Fall 2022.** This meeting is a follow-up to the April 6 VRBPAC meeting that discussed general considerations for future COVID-19 vaccine booster doses and the strain composition of COVID-19 vaccines to further meet public health needs.

**“As we continue to address the ongoing COVID-19 pandemic, there are a number of anticipated submissions and scientific questions that will benefit from discussion with our advisory committee members,”** said Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research. “We are providing a tentative schedule for discussion of these submissions, as these meetings will cover a number of topics that are of great interest to the general public. **The agency is committed to a thorough and transparent process that considers the input of our independent advisors and provides insight into our review of the COVID-19 vaccines. We intend to move quickly with any authorizations that are appropriate once our work is completed.”**

Once the meeting dates are finalized, the FDA intends to make background materials available to the public, including the meeting agenda and committee roster, no later than two business days before each meeting...

::::::

**White House [U.S.]** [to 30 Apr 2022]  
*Briefing Room – Selected Major COVID Announcements*  
*Press Statement - COVID Context*

**[Fact Sheet: Biden Administration Underscores Urgent Need for Additional COVID-19 Response Funding and the Severe Consequences of Congressional Inaction](#)**

April 27, 2022 • Statements and Releases

**[Press Briefing by Press Secretary Jen Psaki and White House COVID-19 Response Coordinator Dr. Ashish Jha](#)**  
April 26, 2022 • Press Briefings

**[FACT SHEET: Biden Administration Increases Access to COVID-19 Treatments and Boosts Patient and Provider Awareness](#)**

April 26, 2022 • Statements and Releases

**Background Press Call by Senior Administration Officials on New Actions to Increase Access to COVID-19 Treatments and Boost Patient and Provider Awareness**

April 25, 2022 • Press Briefings

**USAID** [to 30 Apr 2022]

<https://www.usaid.gov/news-information/press-releases>

*Selected Press Releases, Statements, Announcements*

**The United States Provides an Additional \$13.9 Million to Support Madagascar**

April 29, 2022

The United States through the U.S. Agency for International Development (USAID) is providing an additional \$13.9 million in funding to Madagascar. Of the \$13.9 million in new funding, \$5.4 million will go to the country's COVID-19 response, and \$8.5 million will support small and medium enterprises and economic empowerment for people with disabilities.

**The United States Provides an Additional \$13.9 Million to Support Madagascar**

April 29, 2022

The United States through the U.S. Agency for International Development (USAID) is providing an additional \$13.9 million in funding to Madagascar. Of the \$13.9 million in new funding, \$5.4 million will go to the country's COVID-19 response, and \$8.5 million will support small and medium enterprises and economic empowerment for people with disabilities.

**2022 Interagency Report on the Implementation of the Presidential Memorandum on Advancing the Human Rights of LGBTQI+ Persons Around the World**

April 28, 2022

Statement by Administrator Samantha Power

I applaud the release of the historic 2022 U.S. Interagency Report on the Implementation of the Presidential Memorandum on Advancing the Human Rights of LGBTQI+ Persons Around the World. The report puts a timely spotlight on affirmative efforts of the U.S. government, in partnership with LGBTQI+ leaders, civil-society organizations, rights advocates, and a range of partners, to defend the human rights and dignity of LGBTQI+ persons in every region of the world and across sectors.

**Biden Administration Announces Hundreds of Millions of Dollars in Global Food Aid to Respond to Putin's Unprovoked Invasion of Ukraine**

April 27, 2022

Today, the Biden Administration announced that the U.S. Agency for International Development (USAID) and the U.S. Department of Agriculture (USDA) are taking the extraordinary step to draw down the full balance of the Bill Emerson Humanitarian Trust (BEHT) as part of an effort to provide \$670 million in food assistance to countries in need as a result of Putin's unprovoked invasion of Ukraine. The world is suffering from historic levels of global food insecurity, which is being exacerbated by the impact Russia's war on Ukraine is having on global food supplies. Available estimates suggest that an additional 40 million people could be pushed into poverty and food insecurity as a result of Russia's aggression.

**United States Providing More Than \$200 Million in Additional Humanitarian Assistance for the Horn of Africa**

April 26, 2022

Today in Geneva, the United States announced more than \$200 million in additional assistance to respond to humanitarian needs in the Horn of Africa, including from the devastating drought and to address the needs of refugees, internally displaced persons, and conflict-affected population in the region. This assistance, through the U.S. Agency for International Development (USAID) and the U.S. Department of State will help save lives in Ethiopia, Kenya, and Somalia, where more than 20 million people are projected to need emergency food assistance this year following two years of inadequate rainfall in a region dependent on agriculture and livestock to survive.

:::::::  
::::::

## **Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **European Medicines Agency**

[News & Press Releases](#)

[Press Releases](#)

**[News: European Immunization Week 2022: Statement by Executive Director Emer Cooke - Why vaccines contribute to a "Long Life for All" \(new\)](#)**

Last updated: 25/04/2022

::::::

### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

[Latest Updates \[Selected\]](#)

[Publication](#)

**[Hepatitis of unknown origin - Reporting protocol 2022](#)**

Technical guidance - 29 Apr 2022

This reporting protocol is intended for reporting national case-based data for surveillance of hepatitis of unknown origin from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA), to the European level.

::::::



**European Centre for Disease Prevention and Control**

COVID-19 Vaccine Tracker

Cumulative vaccine uptake (%) in the total population in EU/EEA countries

At least one dose	Primary course	Booster/additional dose
75.2%	72.4%	51.4%

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-04-29

Accessed 29 Apr 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

::::::

## **European Commission**

<https://ec.europa.eu/commission/presscorner/home/en>

*Latest [Selected]*

*Statement 29 April 2022*

**Commission statement on the resignation of Fabrice Leggeri [Frontex]**

*Press release 28 April 2022*

**EU and international partners put forward a Declaration for the Future of the Internet**

Today, the European Union, the United States, and several international partners have proposed a Declaration for the Future of the Internet, setting out the vision and principles of a trusted Internet.

Speech 27 April 2022 Brussels

**Speech by Vice-President Jourová on abusive lawsuits against journalists and human rights defenders 'SLAPPs'**

*Press release 26 April 2022*

**Food security in Horn of Africa: EU steps up support to drought-affected countries**

A devastating climate-induced drought is affecting the Horn of Africa. The situation is worsened by the impact of COVID-19, conflict and insecurity situation in the region, as well as the expected aggravation of food insecurity and nutrition due to Russia's invasion of Ukraine.

*Press release 25 April 2022*

**Russian war crimes in Ukraine: Commission proposes to reinforce the mandate of Eurojust to collect and preserve evidence of war crimes**

Today, the Commission has proposed to amend the Eurojust Regulation to give the Agency the legal possibility to collect, preserve and share evidence on war crimes.

::::::

::::::

## **Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**

<https://africacdc.org/covid-19-vaccination/>

Vaccines received from COVAX


**51**  
Countries

Vaccines received bilaterally

**52**  
Countries

Vaccines received from AVATT

**38**  
Countries



:::::::  
::::::

## Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

Latest Updates [Selected]

[No new digest content identified; last announced at 28.03.2022]

:::::::  
::::::

## India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :  
30 April 2022, 08:00 IST  
(GMT+5:30)

(↑↓ Status change since  
yesterday)

**Active (0.04%)**

**18684 (883↑)**

**Discharged (98.74%)**

**42533377 (2755↑)**

**Deaths (1.22%)**

**523803 (50↑)**

COVID-19 Vaccination  
as on : 30 April 2022,  
08:00 IST (GMT+5:30)

**Total Vaccination : 1,88,89,90,935 (22,58,059↑)**

**Government of India – Press Information Bureau**

Latest Press Releases

**COVID - 19 Vaccination Update - Day 470**

:: India's cumulative vaccination coverage crosses 189 Crore landmark milestone

:: More than 23 lakh Vaccine doses administered today till 7 pm

*Posted On: 30 APR 2022 8:02PM by PIB Delhi*

**Indian Council for Medical Research (ICMR)**

<https://www.icmr.gov.in/media.html>

*Press Releases*

*No new digest content identified.*

:::::

:::::

**China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

*[We did not identify official announcements about Shanghai confirming the reports below; See China CDC below for additional announcements]*

**Shanghai marks COVID milestone, Beijing on edge**

By Brenda Goh and Min Zhang

- Shanghai records no COVID cases outside quarantine areas
- Beijing on tenterhooks, bracing for more restrictions
- Breakthrough would mark victory for Xi in crucial year
- Infections ease as China starts Labour Day holiday

SHANGHAI/BEIJING, April 30 (Reuters) - Shanghai said on Saturday it had detected no new daily COVID-19 cases outside quarantine areas, marking a milestone in its battle to contain the virus, which has paralysed the city of 25 million and put residents in the capital Beijing on edge.

Streets in Beijing were eerily quiet at the start of a five-day Labour Day break, with residents anxious that authorities would impose further restrictions during a holiday when many typically travel or socialise...

...Beijing will also implement a further two rounds of COVID tests on May 1 and May 3 in its most populous district of Chaoyang, known for its night life, malls and embassies.

The city will halt all restaurant dining between May 1 and 4, an official from the local commerce bureau said, calling for residents to "cook at home".

Officials have provided no timeline or strategy for returning to some semblance of normality.

**Nomura estimates 46 cities are in full or partial lockdowns, affecting 343 million people. Societe Generale estimates that provinces experiencing significant restrictions account for 80% of China's economic output.**

In response to COVID and other headwinds, China will step up policy support for the economy, a top decision-making body of the Communist Party said on Friday, lifting stocks from two-year lows. [read more](#)

Shanghai reported 47 COVID-19 deaths for Friday, down from 52 a day earlier. Some have questioned the fatality rate, as many residents have said relatives or friends have died after catching coronavirus as early as March.

Beijing has reported 295 new COVID-19 cases since April 22, the local health authority said, of which 123 cases were found in the Chaoyang district.

Overall, mainland China reported 10,793 daily COVID-19 cases, down from 15,688 new cases a day earlier, the National Health Commission said on Saturday...

:::::

:::::

## **GPEI Polio**

### **[Polio this week as of 27 April 2022](#)**

#### *Headlines*

:: This week, Global Polio Eradication Initiative (GPEI) partners launched the '[Investment Case](#)' for polio eradication, at a virtual event. The Investment Case is the GPEI sister-document to the Polio Eradication Strategy 2022-2026, and outlines the humanitarian and economic benefits of polio eradication. During the event, the Government of Germany, which holds G7 presidency in 2022, announced that the country will co-host a pledging moment for the GPEI Strategy during the 2022 World Health Summit in October. A recording of the virtual event is available online [here](#).

:: Rotary International President Shekhar Mehta, WHO GPEI Director Aidan O'Leary and Dr Sarthak Das, Chief Executive Officer of the Asia Pacific Leaders Malaria Alliance offer their views on what lessons and experiences from polio and malaria can be drawn for existing and future pandemics, in an op-ed published in Health Policy Watch. Read it [here](#).

:: Comprehensive outbreak response in Tajikistan successfully stops outbreak: an outbreak response assessment concluded that a cVDPV2 outbreak that started in January 2021 has been stopped, thanks to comprehensive and rapid response with novel oral polio vaccine type 2 (nOPV2). [More](#)

#### ***Summary of new polioviruses this week:***

- Pakistan:** one WPV1 case and one positive environmental sample
- DR Congo:** four cVDPV2 cases
- Israel:** 13 cVDPV3 positive environmental samples
- Nigeria:** one cVDPV2 case
- Occupied Palestinian territory:** seven cVDPV3 positive environmental samples
- Somalia:** one cVDPV2 case

### **[Polio transition planning and polio post-certification](#)**

27 April 2022 *Meeting report*

*Overview*

The Executive Board at its 150th session noted an earlier version of this report.<sup>1</sup> The present report provides an update on the implementation of the Strategic Action Plan on Polio Transition (2018–2023)<sup>2</sup> at the start of 2022, within the context of the coronavirus disease (COVID-19) pandemic.

::::::

::::::

## **UN OCHA – Current Emergencies**

*Current Corporate Emergencies*

### **Afghanistan**

*No new updates identified.*

### ***Northern Ethiopia***

#### **Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 29 Apr 2022**

##### **HIGHLIGHTS**

- 3,400 MT of food brought into Tigray between 1 and 25 April. At least 4,675 MT of food are required every day to complete current food distribution by mid-May.
- More than 46,000 students across 144 schools in Wag Hemra Zone, South Wello, North Wello Oromia zones of Amhara Region received school feeding services during the reporting week.
- Some 16,500 IDPs in Amhara Region have been assisted with essential NFI kits during this reporting week.
- 82,884 people received food assistance in Fanti Rais and Kilbati Rasu zones in Afar during the reporting period and overall 698,503 people assisted as of 25 April.

### **Ukraine**

#### **Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 26 April 2022)**

::::::

::::::

### **WHO & Regional Offices [to 30 Apr 2022]**

<https://www.who.int/news>

*News [Selected]*

29 April 2022

Statement

#### **Quadrilateral Memorandum of Understanding (MoU) signed for a new era of One Health collaboration**

27 April 2022

Joint News Release

#### **UNICEF and WHO warn of perfect storm of conditions for measles outbreaks, affecting children**

*[See Milestones above for detail]*

27 April 2022

Departmental news

#### **WHO launches a second report of country success stories in mitigating the impact of the COVID-19 pandemic on TB services**

::::::

**WHO Director General Speeches** [selected]  
<https://www.who.int/director-general/speeches>

*Selected*

27 April 2022

Speech

**[WHO Director-General's opening remarks at the 10th meeting of the Access to COVID-19 Tools Accelerator Facilitation Council](#)** – 26 April 2022

27 April 2022

Speech

**[WHO Director-General's remarks at the Investment Case for Polio Eradication](#)** – 26 April 2022

27 April 2022

Speech

**[WHO Deputy Director-General's speech at the OECD Council on the 2030 Agenda for Sustainable Development: Session 2: Global health challenges in the era of COVID-19](#)**

26 April 2022

Speech

**[WHO Director-General's opening remarks at the WHO press conference](#)** – 26 April 2022

25 April 2022

Speech

**[WHO Director-General's panel remarks at the Group of Friends of Global Health](#)** – 25 April 2022

25 April 2022

Speech

**[WHO Director-General's opening remarks at the Working Group on Sustainable Finance, final meeting](#)** – 25 April 2022

::::::

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**[WHO African Region](#)**

- :: 29 April 2022 [Ghana finds success in COVID-19 mass vaccination campaigns](#)
- :: 29 April 2022 [Speedy vaccination campaign helps stop cholera outbreak in Niger](#)
- :: 28 April 2022 [Vaccine-preventable disease outbreaks on the rise in Africa](#)

**[WHO Region of the Americas PAHO](#)**

:: 29 Apr 2022

[Environmental surveillance - complementary tool for tracking COVID-19](#)

Over 60 countries, including several in the Americas, are using wastewater monitoring to track SARS-CoV-2 in communities, with over 3,300 active sites. Washington, D.C., April 29, 2022 (PAHO) -- New guidance from the World Health Organization (WHO) provides advice to countries on sampling and testing for the SARS-CoV2 virus in untreated...

:: 25 Apr 2022

[PAHO Director calls for immunization gaps to be closed for all vaccines, including COVID-19](#)

2.7 million children in the Americas did not receive the vaccines needed to keep them healthy in 2020, while around 230 million people have still not received a single dose of COVID-19 vaccine in the region  
Roseau, Dominica, 25 April 2022 (PAHO) – In 2020, 2.7 million children in the Americas did not receive the essential vaccines needed to keep...

:: 25 Apr 2022

[World Malaria Day – More must be done to improve malaria response at the local level](#)

Washington D.C., 25 April 2022 (PAHO) – On World Malaria Day, the Pan American Health Organization (PAHO) urges countries to step-up efforts to tackle malaria in the region, calling for prevention, diagnosis and treatment interventions that are data-led and tailored to local contexts. While in 2020, the 18 endemic countries of the Americas...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

- :: [WHO re-assigns Islands and Small States Institute in Malta as collaborating centre](#) 29-04-2022
- :: [HPV vaccination brings the WHO European Region closer to a cervical cancer-free future](#) 29-04-2022
- :: [Comprehensive outbreak response successfully stops spread of polio in Tajikistan](#) 28-04-2022
- :: [Ukraine: Immediate steps needed to prevent a measles outbreak due to the ongoing war and low vaccination rates, warns WHO](#) 28-04-2022
- :: [Countries across the WHO European Region celebrate World Health Day 2022](#) 27-04-2022

### **WHO Eastern Mediterranean Region EMRO**

- :: [WHO marks 5 years of strategic partnership with USAID in Iraq](#) 26 April 2021

### **WHO Western Pacific Region**

- :: [25 April 2022 News release](#)
- [WHO announces winners of inaugural Western Pacific Innovation Challenge](#)

::::::

### **Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[28 April 2022 | Ebola virus disease - Democratic Republic of the Congo](#)

[28 April 2022 | Japanese encephalitis - Australia](#)

[27 April 2022 | Multi-country outbreak of Salmonella Typhimurium linked to chocolate products – Europe and the United States of America](#)

27 April 2022 | Cholera - Malawi

27 April 2022 | Measles - Somalia

25 April 2022 | Yellow Fever – Uganda

::::::

### **WHO Events**

<https://www.who.int/news-room/events/1>

*[Selected]*

**Indigenous peoples and tackling health inequities: WHO side event at the 21st session of the UN Permanent Forum on Indigenous Issues**

3 May 2022 17:00 – 18:30 CET

**Launch of the Child Health and Well Being Dashboard**

4 May 2022 15:30 – 17:00 CET

::::::

### **New WHO Publications**

<https://www.who.int/publications/i>

*Selected Titles*

28 April 2022

**Integration of mental health and HIV interventions**

28 April 2022

**Emergency in Ukraine: external situation report #9, published 28 April 2022: reporting period: 21–27...**

27 April 2022

**Polio transition planning and polio post-certification**

*Overview*

The Executive Board at its 150th session noted an earlier version of this report.<sup>1</sup> The present report provides an update on the implementation of the Strategic Action Plan on Polio Transition (2018–2023)<sup>2</sup> at the start of 2022, within the context of the coronavirus disease (COVID-19) pandemic.

27 April 2022

**Strengthening pandemic preparedness planning for respiratory pathogens: policy brief, 27 April 2022**

*Overview*

This policy brief outlines core elements that Member States are encouraged to a) develop an integrated approach to respiratory pathogen pandemic preparedness planning and b) enhance national and sub-national functional capacities for preparedness. In addition, this policy brief highlights suggested actions for Member States as they initiate or update national and sub-national pandemic preparedness planning process.

25 April 2022

**Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 25 April 2022: updated chapter: mask use, part 1: health care settings**

25 April 2022

**WASH FIT: A practical guide for improving quality of care through water, sanitation and hygiene in health...**

25 April 2022

**Integrated care for older people (ICOPE) implementation pilot programme**

::::::  
::::::  
::::::

**CDC/ACIP [U.S.]** [to 30 Apr 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

**Transcript for CDC Media Telebriefing: Update on COVID-19**

Thursday, April 28, 2022

::::::

**ACIP Meetings**

Next ACIP Meeting

**June 22-23**

*No Agenda posted at inquiry*

::::::

**MMWR Weekly: Current Volume (71) April 29 2022 / No. 17**

**PDF of this issue**

- [Public Health Actions to Control Measles Among Afghan Evacuees During Operation Allies Welcome — United States, September–November 2021](#)
- [Provisional COVID-19 Age-Adjusted Death Rates, by Race and Ethnicity — United States, 2020–2021](#)
- [Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022](#)
- [Notes from the Field: Response to Measles Among Persons Evacuated from Afghanistan — Joint Base McGuire-Dix-Lakehurst, New Jersey, August–October 2021](#)

::::::

**Coronavirus Disease 2019 (COVID-19)- CDC**

*Approximately 25 announcements/reports/data summaries.*

:: 4/29/22 [Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 29 Apr 2022 06:00:00 EST](#)

::::::

:::::

**Africa CDC** [to 30 Apr 2022]

<http://www.africacdc.org/>

*News*

**The Democratic Republic of Congo Declared Ebola Virus Disease (EVD) Outbreak in Mbandaka, Equateur Province**

25 April 2022

:::::

:::::

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 30 Apr 2022]

<http://en.nhc.gov.cn/>

*News*

**April 30: Daily briefing on novel coronavirus cases in China**

On April 29, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 1,424 new cases of confirmed infections.

**National Medical Products Administration – PRC** [to 30 Apr 2022]

<http://english.nmpa.gov.cn/>

*News*

**Nearly 3.34b COVID-19 vaccine doses administered on the Chinese mainland**

2022-04-29

Nearly 3.34 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed Thursday.

**CCDC Weekly Reports: Current Volume (4)**

2022-04-29 / No. 17 ***OCCUPATIONAL CANCER ISSUE***

[View PDF of this issue](#)

:::::

***Contents [click to move among sections]***

*:: [Coronavirus \[COVID-19\] - WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

:::::

## **Organization Announcements**

### *Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Airfinity** [to 30 Apr 2022]

<https://www.airfinity.com/insights>

*INSIGHTS & COMPANY NEWS*

**[Global sales estimate for COVID-19 antiviral pills increased by 60% to \\$32.5bn](#)**

Published by Airfinity

Apr 21, 2022

Airfinity has released its latest COVID-19 treatments revenue forecast for Q1 2022 and 2022.

**Paul G. Allen Frontiers Group** [to 30 Apr 2022]

<https://alleninstitute.org/news-press/>

*News*

**[News from the Allen Institute: April 2022](#)**

April 28, 2022

Highlights include: a new Lab Notes podcast on why we don't understand the brain, new research about how neurons connect, day-in-the-life features of our neuroscience labs and more.

**BMGF - Gates Foundation** [to 30 Apr 2022]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 30 Apr 2022]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 30 Apr 2022]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 30 Apr 2022]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

:: Past weekly editions and posting of all segments of **Vaccines and Global Health: The Week in Review** are [available here](#).

:: [Informed Consent: A Monthly Review – April 2022](#) is now posted [here](#)

:: [Statement on ICF \[Informed Consent Form\] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse](#)

:: [Patients, Politics, Pressure :: Pharma Stays Steady \[Mostly\] In Russia Sanctions Context Observations at 30 March 2022](#) David R Curry

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 30 Apr 2022]

<http://cepi.net/>

*Latest News*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 30 Apr 2022]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 30 Apr 2022]

<https://dukeghic.org/>

*Our Blog*

*No new digest content identified.*

**EDCTP** [to 30 Apr 2022]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

29 April 2022

[Belgium and Côte d'Ivoire join EDCTP Association](#)

25 April 2022

[World Malaria Day 2022: EDCTP supports innovative approaches to fight malaria](#)

**Emory Vaccine Center** [to 30 Apr 2022]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

**Emory/Georgia funded TRAC by NIAID**

NIH Funds New Tuberculosis Research Advancement Centers

**European Vaccine Initiative** [to 30 Apr 2022]

<http://www.euvaccine.eu/>

*Latest News, Events*

**"Vaccines provide everyone a chance at a fulfilling life"**

World Immunization Week: 24 – 30 April 2022

**Evidence Aid** [to 30 Apr 2022]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*New Resources*

**Prophylactic anticoagulants for hospitalized COVID-19 patients (search up to 14 April 2021) Added April 25, 2022**

**Fondation Mérieux** [to 30 Apr 2022]

<http://www.fondation-merieux.org/>

*News, Events*

*Mérieux Foundation & University of Geneva co-organized event*

**22nd Advanced Vaccinology Course (ADVAC)**

May 9 - 20, 2022 - Les Pensières Center for Global Health, Veyrier-du-Lac (France)

**Gavi** [to 30 Apr 2022]

<https://www.gavi.org/>

*News Releases*

27 April 2022

**Amref health Africa appointed by Gavi as the new Civil Society Organisation (CSO) host**

- The Gavi CSO Constituency is a diverse group made up of over 4000 CSOs from around the world aimed at ensuring that every child and person is reached with immunisation.
- As Gavi CSO host, Amref will mobilise and support civil society organisations working to strengthen health systems and deliver immunisation services to underserved communities.
- Amref Health Africa is the first organisation located in a lower middle-income country to host the CSO platform

**GHIT Fund** [to 30 Apr 2022]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 30 Apr 2022]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

25 April 2022

### **Global Fund Urges the World to Boost the Fight Against Malaria as COVID-19 Disruptions, Drug and Insecticide Resistance and New Threats Endanger Progress**

Ahead of World Malaria Day, 25 April, the Global Fund calls for renewed commitment in the fight against malaria, a disease that now kills one child every minute. After years of steady declines, malaria cases and deaths are on the rise mainly due to s...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 30 Apr 2022]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified*

**Hilleman Laboratories** [to 30 Apr 2022]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified*

**HHMI - Howard Hughes Medical Institute** [to 30 Apr 2022]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Vaccines Project** [to 30 Apr 2022]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 30 Apr 2022]

<https://www.iavi.org/>

*Latest News*

*No new digest content identified.*

**ICRC** [to 30 Apr 2022]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

### **Taking COVID-19 vaccines to remote areas in Mindanao**

This is primarily because many are unable to bear the cost of travelling to a vaccine centre in the main city while others fear getting the vaccination owing to misinformation and lack of awareness. As a result, their families and communities remain v

29-04-2022 | Article

### **ICRC appoints a new member to governing body**

Geneva (ICRC) – At its meeting on 27 April, the Assembly of the International Committee of the Red Cross (ICRC) appointed Ms Samia Hurst-Majno as its newest member.

28-04-2022 | News release

### **Table of National Committees and other national bodies on international humanitarian law**

26 April 2022

### **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

### **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

### **IFRC [to 30 Apr 2022]**

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

27/04/2022

### **Vaccinations vital as COVID cripples Pacific countries**

Kuala Lumpur/Suva 28 April 2022 – The International Federation of Red Cross and Red Crescent Societies are increasingly concerned for more than 1 million people in Pacific nations as they struggle with their first major wave of COVID-19 fuelled by the Omicron variants.

Ramping up vaccinations is vital as the rapid surge in COVID infections is causing increasing death and illness in countries with low immunisation rates.

COVID-free for almost two years, Vanuatu, the Solomon Islands, Tonga, Kiribati, and Samoa have all experienced outbreaks in their capitals, and the virus is spreading to vulnerable outer island communities which lack basic treatment and vaccination facilities.

The virus is putting huge strains on fragile healthcare systems in population centres such as Honiara, Port Vila and Nuku'alofa. A rising number of healthcare workers are being struck down with COVID-19, further limiting health services and escalating the crisis...

26/04/2022

### **KwaZulu-Natal floods: Red Cross steps up response amid mounting humanitarian needs**

### **Institut Pasteur [to 30 Apr 2022]**

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**IOM / International Organization for Migration** [to 30 Apr 2022]

<http://www.iom.int/press-room/press-releases>

*News - Selected*

*News Global*

29 April 2022

**[IOM Appeals for USD 514 Million to Support Ukraine Response](#)**

**ISC / International Science Council** [to 30 Apr 2022]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*News Blogs Podcasts Events*

*Blogs*

**[Vaccine promotion remains a key focus for this year's Day of Immunology](#)**

29.04.2022

On this International Day of Immunology, join ISC Member the International Union of Immunological Societies (IUIS) in celebrating the theme of vaccines with promotional and educational activities.

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

**[2022 International Day of Immunology](#)**

April 26, 2022

**IVAC** [to 30 Apr 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 30 Apr 2022]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 30 Apr 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

**[Johns Hopkins Center for Health Security's COVID-19 Testing Toolkit Launches New FAQs Tool](#)**

April 28, 2022

**MSF/Médecins Sans Frontières** [to 30 Apr 2022]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Sudan*

**[Violent attacks leave tens of thousands without access to healthcare in West Darfur](#)**

Project Update 29 Apr 2022

*Access to medicines*

**["Broken" humanitarian COVID-19 vaccine system delays vaccinations](#)**

Press Release 27 Apr 2022

*[See Perspectives above for detail]*

**National Academy of Medicine** - USA [to 30 Apr 2022]

<https://nam.edu/programs/>

*News [Selected]*

**[NAM to Deliver National Plan to Strengthen Health Workforce Well-Being and Restore the Health of the Nation](#)**

April 28, 2022

The National Academy of Medicine (NAM) Action Collaborative on Clinician Well-Being and Resilience is working urgently to develop a National Plan for health workforce well-being. The draft plan will be released in May 2022 for public input and builds on almost six years of collective work among 200 Clinician Well-Being Collaborative members and network organizations. [...]

**National Academy of Sciences** - USA [to 30 Apr 2022]

<http://www.nasonline.org/news-and-multimedia/>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 30 Apr 2022]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 30 Apr 2022]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

**OECD** [to 30 Apr 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

*Newsroom/Library*

## **OECD countries advancing slowly on sustainable development targets by 2030**

Despite progress made since the adoption of the 2030 Agenda for Sustainable Development and its 17 Goals (SDGs), OECD countries have met or are close to meeting only a quarter of the targets for which performance can be gauged, according to a new OECD report.

27 April 2022

**PATH** [to 30 Apr 2022]

<https://www.path.org/media-center/>

*Press Releases*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 30 Apr 2022]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 30 Apr 2022]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

28 April 2022

**Key considerations to integrate HIV and mental health interventions**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 30 Apr 2022]

<http://www.unhcr.org/en-us/media-centre.html>

*Selected News Releases, Announcements*

*No new digest content identified.*

**UNICEF** [to 30 Apr 2022]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]*

*Press release*

04/27/2022

**UNICEF and WHO warn of 'perfect storm' of conditions for measles outbreaks, affecting children**

<https://www.unicef.org/press-releases/unicef-and-who-warn-perfect-storm-conditions-measles-outbreaks-affecting-children>

NEW YORK/ GENEVA, 27 April 2022 – An increase in measles cases in January and February 2022 is a worrying sign of a heightened risk for the spread of vaccine-preventable diseases and could trigger larger outbreaks, particularly of measles affecting millions of children in 2022, warn WHO and UNICEF. Pandemic-related disruptions, increasing...

*[See Perspectives above for detail]*

*Press release*

04/26/2022

**Global polio eradication initiative calls for renewed commitments to achieve promise of a polio-free world**

<https://www.unicef.org/press-releases/global-polio-eradication-initiative-calls-renewed-commitments-achieve-promise-polio>

GENEVA, 26 April 2022 – Today, the Global Polio Eradication Initiative (GPEI) announced that it is seeking new commitments to fund its 2022-2026 Strategy at a virtual event to launch its investment case. The strategy, if fully funded, will see the vaccination of 370 million children annually for the next five years and the continuation of global...

*Press release*

04/25/2022

**1 in 4 children in Latin America and the Caribbean are exposed to diseases that can be prevented with vaccines**

<https://www.unicef.org/press-releases/1-4-children-latin-america-and-caribbean-are-exposed-diseases-can-be-prevented>

PANAMÁ CITY, 25 April 2022 – In five years, the complete vaccination schedule for diphtheria, tetanus and pertussis (DTP3) in Latin America and the Caribbean has dropped from 90 percent in 2015 to 76 percent in 2020, according to data from the Pan American Health

*[See Perspectives above for detail]*

**Unitaid** [to 30 Apr 2022]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 30 Apr 2022]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 30 Apr 2022]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*World Immunization Week 2022*

**Working Toward a Long Life for All with Dr. Ashmita Gupta and Dr. Salvia Zeeshan!**

April 26, 2022

**Vaccine Confidence Project** [to 30 Apr 2022]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 30 Apr 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 30 Apr 2022]

<https://wellcome.ac.uk/news>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 30 Apr 2022]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**WFPDA: World Federation of Public Health Associations** [to 30 Apr 2022]

<https://www.wfpha.org/>

*Latest News - Blog*

*No new digest content identified.*

**World Bank** [to 30 Apr 2022]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

#### **[COVID-19 Vaccine Inequities and Hesitancy in Iraq](#)**

Starting in August 2020, the World Bank collaborated with the World Food Programme (WFP) and implemented nine (9) rounds of the Iraq High Frequency Phone Survey (IHFPS) as part of the WFP's monthly mVAM...

Date: April 28, 2022 Type: Publication

#### **[World Bank, Partners Launch New Fund to Spur Smart Investments in Childcare](#)**

WASHINGTON, April 28, 2022—The World Bank and government and foundation partners today launched a new program to scale up quality, affordable childcare in developing countries – a critical investment to...

Date: April 28, 2022 Type: Press Release

#### **[Keynote Address: Breaking the Cycle of Neglect and Panic](#)**

We are meeting to discuss the issues of preparedness and response after more than two years of a global Pandemic. Although the situation has improved, we still need to be cautious given the case numbers...

Date: April 27, 2022 Type: Speeches and Transcripts

*[See Week in Review above for detail]*

**World Customs Organization – WCO** [to 30 Apr 2022]

<http://www.wcoomd.org/>

*Latest News*

*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 30 Apr 2022]

<https://www.oie.int/en/media/news/>

*Press Releases, Statements*

*No new digest content identified.*

**WTO - World Trade Organisation** [to 30 Apr 2022]

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events [Selected]*

**[Members discuss improving data collection on trade in essential goods to fight COVID-19](#)**

26 April 2022

The Committee on Market Access held on 26 April the second experience-sharing session on COVID-19-related goods, with members reporting on how they have monitored and measured trade in essential goods to combat the pandemic. They also discussed ways to improve data collection at a time of crisis. In addition, members explored how to promote greater international cooperation to better track the trade flows of value chains for the manufacturing of essential COVID-19-related products.

**[DG Okonjo-Iweala: Trade has central role in addressing food security challenges](#)**

26 April 2022

Record food prices and a worsening food security context have given new urgency to the role of trade in addressing the challenges we face today, Director-General Okonjo-Iweala said at a seminar on food security organized by the WTO on 26 April. In her opening remarks, she said the event provided an opportunity to deepen understanding of the issues at stake and to help members take concrete steps forward so that trade can contribute to the attainment of food security around the world.

::::::

**ARM [Alliance for Regenerative Medicine]** [to 30 Apr 2022]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

**[Alliance for Regenerative Medicine Announces CEO Transition](#)**

April 27, 2022 WASHINGTON, DC

Janet Lynch Lambert will step down as the CEO of the Alliance for Regenerative Medicine after guiding the leading international advocacy organization for cell, gene and tissue-engineered therapies through five years of extraordinary growth in membership, funding, and influence. In Lambert's time as the CEO of ARM, the membership doubled to more than 425 diverse global members and the organization's budget and full-time staff tripled...The ARM board has constituted an 8-person Search Committee to conduct the search for a CEO successor, and Lambert is a key member of that committee. Executive search firm Catalyst Advisors, led by Partner Gilbert Forest, has been retained to support the search....

**BIO** [to 30 Apr 2022]

<https://www.bio.org/press-releases>

*Press Release*

**BIO Statement on USTR Special 301 Report**

April 29, 2022

*USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement:*

*"We welcome USTR's efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially concerning China's coercive technology transfer policies, patent prosecution, and patent enforcement obstacles. USTR's emphasis on monitoring China's progress in implementing its Phase One Agreement commitments to address these longstanding IP matters is encouraging..."*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 30 Apr 2022]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 30 Apr 2022]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 30 Apr 2022]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

**Celebrating World IP Day with a focus on youth and innovation**

26 April 2022

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**International Alliance of Patients' Organizations – IAPO** [to 30 Apr 2022]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

*No new digest content identified.*

**PhRMA** [to 30 Apr 2022]

<http://www.phrma.org/>

*Latest News [Selected]*

*No new digest content identified.*

\* \* \* \*

### ***Contents [click to move among sections]***

[:: Coronavirus \[COVID-19\] - WHO](#)  
[:: Organization Announcements](#)  
[:: Journal Watch](#)

\* \* \* \*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

#### **AJOB Empirical Bioethics**

Volume 13, 2022 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

*Article*

#### **[Ethical Reasoning During a Pandemic: Results of a Five Country European Study](#)**

[S. B. Johnson, F. Lucivero, B. M. Zimmermann, E. Stendahl, G. Samuel, A. Phillips & N. Hangel](#)

Pages: 67-78

Published online: 09 Mar 2022

*Article*

#### **[Governing Gene Drive Technologies: A Qualitative Interview Study](#)**

[N. de Graeff, Karin R. Jongsma, Jeantine E. Lunshof & Annelien L. Bredenoord](#)

Pages: 107-124

Published online: 03 Jul 2021

#### **AMA Journal of Ethics**

Volume 24, Number 4: E249-341 Apr 2022

<https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities>

#### ***Health Equity in US Latinx Communities***

Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable

disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

**American Journal of Infection Control**

April 2022 Volume 50 Issue 4 p367-476

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

April 2022 Volume 62 Issue 4 p473-660

<https://www.ajpmonline.org/current>

[Reviewed earlier]

**American Journal of Public Health**

April 2022 112(52)

<http://ajph.aphapublications.org/toc/ajph/current>

**Supplement 2 2022 = Global Opioid Crisis**

**American Journal of Tropical Medicine and Hygiene**

Volume 106 (2022): Issue 2 (Feb 2022)

<https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

March 2022 Volume 175, Issue 3

<http://annals.org/aim/issue>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 305 April 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/305/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 30 Apr 2022)

[No new digest content identified]

**BMJ Global Health**

April 2022 - Volume 7 - 4  
<https://gh.bmjjournals.org/content/7/4>  
[Reviewed earlier]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>  
(Accessed 30 Apr 2022)

### **Integrated delivery of family planning and childhood immunisation services: a mixed methods assessment of service responsiveness**

*Postpartum women represent a considerable share of the global unmet need for modern contraceptives. Evidence suggests that the integration of family planning (FP) with childhood immunisation services could hel...*

Authors: Jessie K. Hamon, Misozi Kambanje, Shannon Pryor, Alice S. Kaponda, Erick Mwale, Helen E. D. Burchett, Susannah H. Mayhew and Jayne Webster

Citation: BMC Health Services Research 2022 22:572

Content type: Research Published on: 28 April 2022

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>  
(Accessed 30 Apr 2022)

### **Robustness analysis for quantitative assessment of vaccination effects and SARS-CoV-2 lineages in Italy**

*In Italy, the beginning of 2021 was characterized by the emergence of new variants of SARS-CoV-2 and by the availability of effective vaccines that contributed to the mitigation of non-pharmaceutical intervent...*

Authors: Chiara Antonini, Sara Calandrini and Fortunato Bianconi

Citation: BMC Infectious Diseases 2022 22:415

Content type: Research Published on: 29 April 2022

### **Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020**

*Yemen has faced one of the worst humanitarian crises in the world since the start of the war in 2015. In 2020; 30 Vaccine Derived Polio Virus type 1 (VDPV1) isolates were detected in Saadah governorate. The ai...*

Authors: Mutahar Ahmed Al-Qassimi, Mohammed Al Amad, Labiba Anam, Khaled Almoayed, Ahmed Al-Dar and Faten Ezzadeen

Citation: BMC Infectious Diseases 2022 22:414

Content type: Research Published on: 29 April 2022

### **Exploration of attitudes regarding uptake of COVID-19 vaccines among vaccine hesitant adults in the UK: a qualitative analysis**

*The aim of this work was to explore barriers and facilitators to uptake of COVID-19 vaccines and to explore views and reactions to efforts to improve vaccine uptake among vaccine hesitant individuals.*

Authors: Sarah Denford, Fiona Mowbray, Lauren Towler, Helena Wehling, Gemma Lasseter, Richard Amlöt, Isabel Oliver, Lucy Yardley and Matthew Hickman

Citation: BMC Infectious Diseases 2022 22:407

Content type: Research Published on: 26 April 2022

**BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 30 Apr 2022)

[No new digest content identified]

**BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 30 Apr 2022)

[No new digest content identified]

**BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 30 Apr 2022)

[No new digest content identified]

**BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 30 Apr 2022)

**[Predictors of COVID-19 vaccine acceptability among health professions students in Vietnam](#)**

*The COVID-19 vaccine hesitancy or refusal has actually been a threat to global health. In the current situation, health professions students are at risk for SARS-CoV-2 infection during their internship at health...*

Authors: Cua Ngoc Le, Uyen Thi To Nguyen and Diem Thi Hoang Do

Citation: BMC Public Health 2022 22:854

Content type: Research Published on: 28 April 2022

**[What are the reasons for refusing a COVID-19 vaccine? A qualitative analysis of social media in Germany](#)**

*Vaccination against COVID-19 has been available in Germany since December 2020. However, about 30% of the population report not wanting to be vaccinated. In order to increase the willingness of the population ...*

Authors: Jana Fieselmann, Kübra Annac, Fabian Erdsiek, Yüce Yilmaz-Aslan and Patrick Brzoska

Citation: BMC Public Health 2022 22:846

Content type: Research Published on: 27 April 2022

**[Pentavalent vaccination in Kenya: coverage and geographical accessibility to health facilities using data from a community demographic and health surveillance system in Kilifi County](#)**

*There is substantial evidence that immunization is one of the most significant and cost-effective pillars of preventive and promotive health interventions. Effective childhood immunization coverage is thus essential...*

Authors: Morris Ogero, James Orwa, Rachael Odhiambo, Felix Agoi, Adelaide Lusambili, Jerim Obure,

Marleen Temmerman, Stanley Luchters and Anthony Ngugi

Citation: BMC Public Health 2022 22:826

Content type: Research article Published on: 25 April 2022

### **A tool for early estimation of influenza vaccination coverage in Spanish general population and healthcare workers in the 2018–19 season: the Gripómetro**

*Electronic vaccine registries are not yet widely established. There is a need to real-time monitor influenza vaccine coverage, which may raise awareness to risk groups and professionals, and eventually allow t...*

Authors: Javier Díez-Domingo, Esther Redondo Margüello, Raúl Ortiz de Lejarazu Leonardo, Ángel Gil de Miguel, José María Guillén Ortega, Jesús Rincón Mora and Federico Martínón-Torres

Citation: BMC Public Health 2022 22:825

Content type: Research Published on: 25 April 2022

### **Factors related to parents' adherence to childhood immunization**

*Immunizations protect children from deadly infectious diseases. Yet, there is still insufficient understanding of the factors associated with parents' non-adherence to immunizations in contexts outside of West...*

Authors: Fatimah Hobani and Eman Alhalal

Citation: BMC Public Health 2022 22:819

Content type: Research Published on: 25 April 2022

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 30 Apr 2022)

### **Improving the reproducibility and integrity of research: what can different stakeholders contribute?**

*Increasing awareness of problems with the reproducibility and integrity of research led the UK Parliament Science and Technology Committee to launch, in July 2021, an inquiry into reproducibility and research ...*

Authors: Malcolm Macleod

Citation: BMC Research Notes 2022 15:146

Content type: Commentary Published on: 25 April 2022

### **BMJ Evidence-Based Medicine**

April 2022 - Volume 27 - 2

<https://ebm.bmj.com/content/27/2>

[Reviewed earlier]

### **BMJ Open**

April 2022 - Volume 12 - 4

<https://bmjopen.bmj.com/content/12/4>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 100(4); 2022 Apr 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/404046/>

[Reviewed earlier]

**Cell**

Apr 14, 2022 Volume 185 Issue 8 p1261-1444

<https://www.cell.com/cell/current>

[Reviewed earlier]

**Child Care, Health and Development**

Volume 48, Issue 3 Pages: 359-511 May 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**

Volume 111, Issue 4 Pages: 705-971 April 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

**Therapeutic Innovations in Neuroscience**

The theme of this issue of *Clinical Pharmacology & Therapeutics* (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

**Clinical Therapeutics**

March 2022 Volume 44 Issue 3 p349-472

<http://www.clinicaltherapeutics.com/current>

*Original Research***Rolling Reviews During COVID-19: The European Union Experience in a Global Context**

Roelie Marinus, Sarah Mofid, Marya Mpandzou, Thomas C. Kühler

Published online: January 09, 2022

p352-363

Open Access

*Reviews***Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World**

Leah Burns, Nadege Le Roux, Robert Kalesnik-Orszulak,...Mathias Hukkelhoven, Frank Rockhold, John O'Donnell

Published online: February 15, 2022

p420-437

Open Access

*Commentaries*

**Beyond Influenza Vaccination: Expanding Infrastructure for Hospital-based Pediatric COVID-19 Vaccine Delivery**

Annika M. Hofstetter, Suchitra Rao, Ravi Jhaveri

Published online: January 26, 2022

p450-455

**Clinical Trials**

Volume 19 Issue 2, April 2022

<https://journals.sagepub.com/toc/ctja/19/2>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 30 Apr 2022]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 114 March 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/114/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 5, Issue 2 / April 2022

<https://www.liebertpub.com/toc/crispr/5/2>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

April 2022 - Volume 35 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>  
[Reviewed earlier]

### **Developing World Bioethics**

Volume 22, Issue 1 Pages: 1-62 March 2022  
<https://onlinelibrary.wiley.com/toc/14718847/current>  
[Reviewed earlier]

### **Development in Practice**

Volume 32, Issue 2, 2022  
<http://www.tandfonline.com/toc/cdip20/current>  
[New issue; No digest content identified]

### **Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 6 - December 2021  
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>  
[Reviewed earlier]

### **Disasters**

Volume 46, Issue 2 Pages: 299-586 April 2022  
<https://onlinelibrary.wiley.com/toc/14677717/current>  
[Reviewed earlier]

### **EMBO Reports**

Volume 23 Issue 4 5 April 2022  
<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 28, Number 4—April 2022  
<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 38 March 2022  
<https://www.sciencedirect.com/journal/epidemics/vol/38/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 44, Issue 2 Pages: 1-40 March–April 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Consent and decisional capacity; Outside experts and IRBs; Therapeutic misconception***

[Reviewed earlier]

### **Ethics & International Affairs**

Winter 2021 (35.4) | December 2021

<https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/>

*TABLE OF CONTENTS*

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 21 (April 2022)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/21/suppl/C>

[New issue; No digest content identified]

### **The European Journal of Public Health**

Volume 32, Issue 2, April 2022

<https://academic.oup.com/eurpub/issue/32/2>

[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 21 (4) 2022

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 49, 2022 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 30 Apr 2022]

[No new digest content identified]

## **Global Health Action**

Volume 15, Issue 1 (2022)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 10, No. 2 April 28, 2022

<http://www.ghspjournal.org/content/current>

*COMMENTARIES*

*Open Access*

### **[End Malaria Faster: Taking Lifesaving Tools Beyond “Access” to “Reach” All People in Need](#)**

Courtney Emerson, Jed Meline, Anne Linn, Julie Wallace, Bryan K. Kapella, Meera Venkatesan and Richard Steketee

Global Health: Science and Practice April 2022, 10(2):e2200118; <https://doi.org/10.9745/GHSP-D-22-00118>

To “reach the unreached” with preventive and curative malaria services, we must know which individuals and communities remain unreached and then bring tailored services from the clinic to the community and home.

### **[Community Health Workers in Pandemics: Evidence and Investment Implications](#)**

Madeleine Ballard, Ari Johnson, Iris Mwanza, Hope Ngwira, Jennifer Schechter, Margaret Odera, Dickson Nansima Mbewe, Roseline Moenga, Prossy Muyingo, Ramatulai Jalloh, John Wabwire, Angela Gichaga, Nandini Choudhury, Duncan Maru, Pauline Keronyai, Carey Westgate, Sabitri Sapkota, Helen Elizabeth Olsen, Kyle Muther, Stephanie Rapp, Mallika Raghavan, Kim Lipman-White, Matthew French, Harriet Napier and Lyudmila Nepomnyashchiy

Global Health: Science and Practice April 2022, 10(2):e2100648; <https://doi.org/10.9745/GHSP-D-21-00648>

Community health workers have long played a critical role in preventing, detecting, and responding to pandemics across the globe. To expand, improve, and institutionalize these services, changes in the approach to bi/multilateral aid and private philanthropic investments in low- and middle-income countries are required.

*VIEWPOINTS*

*Open Access*

### **[Strategies to Promote Health System Strengthening and Global Health Security at the Subnational Level in a World Changed by COVID-19](#)**

Martin Alilio, Neetu Hariharan, Elizabeth Lugten, Kama Garrison, Rhea Bright, Wilberforce Owembabazi, Uwem Inyang, Saad El-Din Hassan and Kelly Saldana

Global Health: Science and Practice April 2022, 10(2):e2100478; <https://doi.org/10.9745/GHSP-D-21-00478>

Structural weaknesses in national health systems have led to huge variations in responses to COVID-19. This calls for a unified approach to health security and essential health services as public health threats and the expectation for health care systems to provide improved access and services at affordable cost increases.

*ORIGINAL ARTICLES*

*Open Access*

**Cost of Delivering Tetanus Toxoid and Tetanus-Diphtheria Vaccination in Vietnam and the Budget Impact of Proposed Changes to the Schedule**

Vu Quynh Mai, Laura Boonstoppel, Kelsey Vaughan, Carl Schutte, Annette Ozaltin, Duong Thi Hong, Nguyen Mai Khanh, Hoang Manh Thang, Tran Tuan Anh and Hoang Van Minh

Global Health: Science and Practice April 2022, 10(2):e2100482; <https://doi.org/10.9745/GHSP-D-21-00482>

This study shows that replacing tetanus toxoid vaccination in Vietnam for girls aged 15–16 years in high-risk areas with routine tetanus-diphtheria vaccination for children aged 7 years mainly through a school-based delivery strategy will likely result in immunization cost savings.

**Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 30 Apr 2022]

[No new digest content identified]

**Global Public Health**

Volume 17, Issue 5 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

***Review Article***

**What makes global healthcare partnerships successful? A systematic review**

Regan Guilfoyle, Alexander D. Morzycki & Abdullah Saleh

Pages: 662-671

Published online: 09 Mar 2021

***ABSTRACT***

Academic communities are increasingly involved in efforts to address the overwhelming burden of disease in low-middle income countries. There is, however, little research dedicated to understanding the best approach to creating a successful and sustainable global healthcare project. Our objective was to review the shared characteristics of successful healthcare partnerships between high- and low-middle income countries. Two independent reviewers conducted a systematic review. Articles, describing collaborative, healthcare partnerships between a high- and low-middle income countries between 1910 and September 2018, were included. Twenty-six articles were included. The majority of collaborations were initiated by either the host institution or as a joint decision between institutions. The primary goal of these collaborations revolved around medical education/training and curriculum development. Two partnerships, after more than a decade of collaboration, had achieved a self-sustaining programme. Lack of funding was identified as a major barrier to sustainability. Successful global healthcare partnerships require true collaboration and equal participation of all partners. Funding should be secured prior to programme development in anticipation of a minimum 10-year project. A minimum list of guidelines has been proposed to improve the chances of both a successful and sustainable collaboration.

**Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 30 Apr 2022]

[No new digest content identified]

## **Health and Human Rights**

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 17 - Issue 2 - April 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 37, Issue 4, April 2022

<https://academic.oup.com/heapol/issue/37/4>

*REVIEWS*

### **Seroprevalence and risk factors of COVID-19 in healthcare workers from 11 African countries: a scoping review and appraisal of existing evidence**

Sophie Alice Müller, Rebekah Ruth Wood, Johanna Hanefeld, Charbel El-Bcheraoui

Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 505–513,

<https://doi.org/10.1093/heapol/czab133>

### **A systematic review of scope and quality of health economic evaluations conducted in Ethiopia**

Daniel Erku, Amanual G Mersha, Eskinder Eshetu Ali, Gebremedhin B Gebretekle, Befikadu L Wubishet

Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 514–522,

<https://doi.org/10.1093/heapol/czac005>

### **What makes working together work? A scoping review of the guidance on North–South research partnerships**

Shirine Voller, Joanna Schellenberg, Primus Chi, Nicki Thorogood

Health Policy and Planning, Volume 37, Issue 4, April 2022, Pages 523–534,

<https://doi.org/10.1093/heapol/czac008>

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 30 Apr 2022]

[No new digest content identified]

## **Human Gene Therapy**

Volume 33, Issue 7-8 / April 2022

<https://www.liebertpub.com/toc/hum/33/7-8>

[New issue; No digest content identified]

**Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 18, Issue 1, 2022

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

**Immunity**

Apr 12, 2022 Volume 55 Issue 4 p575-734

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 30 Apr 2022]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 30 Apr 2022]

[No new digest content identified]

**International Health**

Volume 14, Issue 2, March 2022

<https://academic.oup.com/inthealth/issue/14/2>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 10 (2021): Issue 2 (Dec 2021)

<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol 9, No 1 (2022) January 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>

[Reviewed earlier]

## **International Journal of Epidemiology**

Volume 51, Issue 1, February 2022

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 15 Issue 2, 2022

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/2>

*Table of Contents*

### **The role of social media in promoting citizenship values of international students during the COVID-19 global health crisis**

Thelal Igab Oweis

The purpose of this study, accordingly, is to not only offer insights about Arab international students' stress management and adjustment mechanisms while abroad but also bring to light the extent to which these digital citizens' use of social media networks reinforces their citizenship values and preserves their national identity during the COVID-19 global health crisis.

## **JAMA**

April 26, 2022, Vol 327, No. 16, Pages 1527-1624

<https://jamanetwork.com/journals/jama/currentissue>

*Research Letter*

### **Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households**

Silje B. Jørgensen, MD, PhD; Karin Nygård, PhD; Oliver Kacelnik, MD, PhD; et al.

free access has active quiz

JAMA. 2022;327(16):1610-1611. doi:10.1001/jama.2022.3780

This nationwide registry data study from Norway assesses the secondary attack rate of SARS-CoV-2 variants Delta and Omicron in an effort to estimate the transmissibility of the Omicron variant.

### **Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel**

Limor Friedensohn, MD; Dan Levin, MD; Maggie Fadlon-Derai, MHA; et al.

free access has active quiz

JAMA. 2022;327(16):1611-1612. doi:10.1001/jama.2022.4425

This study assessed whether a third vaccine dose was associated with the risk of myocarditis among military personnel in Israel.

*Viewpoint*

### **Attacks on Health Care in the War in UkraineInternational Law and the Need for Accountability**

Lawrence O. Gostin, JD; Leonard S. Rubenstein, JD

free access has audio

JAMA. 2022;327(16):1541-1542. doi:10.1001/jama.2022.6045

This Viewpoint from Gostin and Rubenstein examine the violence against health care workers and institutions in the war in Ukraine and potential paths to hold those perpetuating such attacks accountable.

[JAMA Medical News Audio:](#) Ukrainian Doctors Share Current Experiences

*Editorial*

[\*\*Catastrophic Health Consequences of the War in Ukraine\*\*](#)

Phil B. Fontanarosa, MD, MBA; Annette Flanigin, RN, MA; Robert M. Golub, MD

*Medical News & Perspectives*

[\*\*Clinical Trials Disrupted During War in Ukraine\*\*](#)

Rita Rubin, MA

free access has audio

JAMA. 2022;327(16):1535-1536. doi:10.1001/jama.2022.5571

This Medical News feature describes how the Russian invasion has disrupted clinical trials in Ukraine as well as Russia.

**JAMA Network**

[\*\*COVID-19 Update April 30, 2022\*\*](#)

*These articles on COVID-19 were published across the JAMA Network in the last week.*

**JAMA Pediatrics**

April 2022, Vol 176, No. 4, Pages 335-428

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

**JBIR Evidence Synthesis**

April 2022 - Volume 20 - Issue 4

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

**Journal of Adolescent Health**

April 2022 Volume 70 Issue 4 p517-696

<https://www.jahonline.org/current>

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 47, issue 2, April 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-2>

[Reviewed earlier]

**Journal of Development Economics**

Volume 156 May 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/156/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

April 2022 - Volume 76 - 4

<https://jech.bmj.com/content/76/4>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 15, Issue 1 Pages: 1-72 March 2022

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 17, Issue 3, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 33, Number 1, February 2022

<https://muse.jhu.edu/issue/47329>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 24, issue 2, April 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-2>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 20, 2022 \_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 225, Issue 4, 15 February 2022

<https://academic.oup.com/jid/issue/225/4>

[Reviewed earlier]

**Journal of Medical Ethics**

April 2022 - Volume 48 - 4

<http://jme.bmjjournals.org/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 9, Issue 1 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

April 2022 Volume 243 p1-246

<http://www.jpeds.com/content/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 30 Apr 2022]

**COVID-19 vaccines: awareness, attitude and acceptance among undergraduate University students**

*The myths and conspiracy theories on the COVID-19 vaccine cause people to be hesitant and maleficent towards the vaccine.*

Authors: Firew Asres and Belachew Umeha

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:32

Content type: Research Published on: 26 April 2022

**Journal of Public Health Management & Practice**

May/June 2022 - Volume 28 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[New issue; No digest content identified]

**Journal of Public Health Policy**

Volume 43, issue 1, March 2022

<https://link.springer.com/journal/41271/volumes-and-issues/43-1>

[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

April 2022 Volume 19 Issue 189

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 29, Issue 2, March 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 96 Number 4 February 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Apr 30, 2022 Volume 399 Number 10336 p1669-1752, e39-e41

<https://www.thelancet.com/journals/lancet/issue/current>

*Articles*

[\*\*Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial\*\*](#)

Trong Toan Nguyen, et al.

*Series*

*Optimising Child and Adolescent Health and Development*

[\*\*Health and development from preconception to 20 years of age and human capital\*\*](#)

Robert E Black, et al.

*Optimising Child and Adolescent Health and Development*

[\*\*Effects of early-life poverty on health and human capital in children and adolescents: analyses of national surveys and birth cohort studies in LMICs\*\*](#)

Cesar G Victora, et al.

**The Lancet Child & Adolescent Health**

Apr 2022 Volume 6 Number 4 p215-278, e13-e15

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Apr 2022 Volume 4 Number 4 e207-e289

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Apr 2022 Volume 10 Number 4 e448-e584

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Apr 2022 Volume 22 Number 4p 427-562, e101-e127

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Apr 2022 Volume 7 Number 4 e291-e390

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Apr 2022 Volume 10 Number 4 p313-420, e34-e43

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 26, issue 3, March 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-3>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 42 Issue 3, April 2022

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 100, Issue 1 Pages: 1-313 March 2022

<https://onlinelibrary.wiley.com/toc/14680009/current>

[New issue; No digest content identified]

## **Nature**

Volume 604 Issue 7907, 28 April 2022

<https://www.nature.com/nature/volumes/604/issues/7907>

Article | 07 March 2022 | Open Access

### **[SARS-CoV-2 is associated with changes in brain structure in UK Biobank](#)**

Gwenaëlle Douaud, Soojin Lee, Stephen M. Smith

After infection with SARS-CoV-2, individuals show a greater reduction in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus; greater changes in markers of tissue damage in regions that are functionally connected to the primary olfactory cortex; and a greater reduction in global brain size.

*Article*

### **[Climate change increases cross-species viral transmission risk](#)**

Colin J. Carlson, et al.

Published: 28 April 2022

#### *Abstract*

At least 10,000 virus species have the capacity to infect humans, but at present, the vast majority are circulating silently in wild mammals<sup>1,2</sup>. However, climate and land use change will produce novel opportunities for viral sharing among previously geographically-isolated species of wildlife<sup>3,4</sup>. In some cases, this will facilitate zoonotic spillover—a mechanistic link between global environmental change and disease emergence. Here, we simulate potential hotspots of future viral sharing, using a phylogeographic model of the mammal-virus network, and projections of geographic range shifts for 3,139 mammal species under climate change and land use scenarios for the year 2070. We predict that species will aggregate in new combinations at high elevations, in biodiversity hotspots, and in areas of high human population density in Asia and Africa, driving the novel cross-species transmission of their viruses an estimated 4,000 times. Because of their unique dispersal capacity, bats account for the majority of novel viral sharing, and are likely to share viruses along evolutionary pathways that will facilitate future emergence in humans. Surprisingly, we find that this ecological transition may already be underway, and holding warming under 2 °C within the century will not reduce future viral sharing. Our findings highlight an urgent need to pair viral surveillance and discovery efforts with biodiversity surveys tracking species' range shifts, especially in tropical regions that harbor the most zoonoses and are experiencing rapid warming.

## **Nature Biotechnology**

Volume 40 Issue 4, April 2022

<https://www.nature.com/nbt/volumes/40/issues/4>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 30 Apr 2022)

[No new digest content identified]

**Nature Genetics**

Volume 54 Issue 4, April 2022

<https://www.nature.com/ng/volumes/54/issues/4>

[Reviewed earlier]

**Nature Human Behaviour**

Volume 6 Issue 4, April 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/4>

[New issue; No digest content identified]

**Nature Medicine**

Volume 28 Issue 4, April 2022

<https://www.nature.com/nm/volumes/28/issues/4>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 23 Issue 4, April 2022

<https://www.nature.com/nrg/volumes/23/issues/4>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 22 Issue 4, April 2022

<https://www.nature.com/nri/volumes/22/issues/4>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 21 Issue 4, April 2022

<https://www.nature.com/nrd/volumes/21/issues/4>

[Reviewed earlier]

**New England Journal of Medicine**

April 28, 2022 Vol. 386 No. 17

<https://www.nejm.org/toc/nejm/medical-journal>

*Original Articles*

**[Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting](#)**

O. Magen and Others

*Review Article*

**[Understanding Vaccine Safety and the Roles of the FDA and the CDC](#)**

H.C. Meissner

*Editorials*

## **Covid-19 Boosters — Where from Here?**

P.A. Offit

In December 10, 2020, Pfizer presented results from a 36,000-person, two-dose, prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine, BNT162b2, to the Food and Drug Administration (FDA).<sup>1</sup> The vaccine was 95% effective at preventing severe illness in all age groups, independent of coexisting conditions or racial or ethnic background. A remarkable result. Six months later, studies showed that protection against severe disease was holding up.<sup>2</sup> The results of these epidemiologic studies were consistent with those of immunologic studies showing long-lived, high frequencies of Covid-19-specific memory B and T cells, which mediate protection against severe disease.<sup>3</sup>

In September 2021, 10 months after the BNT162b2 vaccine had become available, Israeli researchers found that protection against severe illness in people 60 years of age or older was enhanced by a third dose.<sup>4</sup> In response, the Centers for Disease Control and Prevention (CDC) recommended that people 65 years of age or older should receive three doses of an mRNA vaccine.

In a study now reported in the Journal,<sup>5</sup> Israeli researchers found that in a study population with a median age of 72 years, protection against severe disease was further enhanced by a fourth dose of mRNA vaccine during the wave of infections caused by the B.1.1.529 (omicron) variant of SARS-CoV-2. These findings were considered by the FDA and CDC in their decision-making process regarding the use of an additional booster dose of mRNA vaccine for people 50 years of age or older.

What about booster dosing for persons who are younger? One year after the BNT162b2 vaccine became available, studies in the United States showed that a third dose of vaccine also enhanced protection against severe disease for people as young as 18 years of age.<sup>6,7</sup> Unfortunately, these studies did not stratify patients according to whether they had coexisting conditions. Therefore, it was unclear who among these younger age groups most benefited from an additional dose. Nonetheless, the CDC later recommended that everyone 12 years of age or older should receive three doses of BNT162b2, regardless of whether risk factors were present. This universal booster recommendation led some summer camps, high schools, universities, hospitals, and businesses to require three doses of mRNA vaccine. In February 2022, in a study that did not support the booster recommendation for children, CDC researchers found that two doses of BNT162b2 induced long-lived protection against serious illness in children 12 to 18 years of age.<sup>8</sup>

In addition to protection against severe disease, the initial phase 3 trial of BNT162b2 — which was performed over a period of several months — also showed 95% protection against mild illness.<sup>1</sup> Unlike protection against severe illness, however, protection against mild illness, which is mediated by high titers of virus-specific neutralizing antibodies at the time of exposure, declined after 6 months, as would have been expected.<sup>2</sup> In response, studies by Pfizer were published in which a booster dose was shown to restore protection against mild illness<sup>9</sup>; unfortunately, this protection did not persist for more than a few months.<sup>6</sup> Short-lived protection against mild illness will limit the ability of booster dosing to lessen transmission.

People are now confused about what it means to be fully vaccinated. It is easy to understand how this could happen. Arguably, the most disappointing error surrounding the use of Covid-19 vaccines was the labeling of mild illnesses or asymptomatic infections after vaccination as “breakthroughs.” As is true

for all mucosal vaccines, the goal is to protect against serious illness — to keep people out of the hospital, intensive care unit, and morgue. The term “breakthrough,” which implies failure, created unrealistic expectations and led to the adoption of a zero-tolerance strategy for this virus. If we are to move from pandemic to endemic, at some point we are going to have to accept that vaccination or natural infection or a combination of the two will not offer long-term protection against mild illness.

In addition, because boosters are not risk-free, we need to clarify which groups most benefit. For example, boys and men between 16 and 29 years of age are at increased risk for myocarditis caused by mRNA vaccines.<sup>10</sup> And all age groups are at risk for the theoretical problem of an “original antigenic sin” — a decreased ability to respond to a new immunogen because the immune system has locked onto the original immunogen. An example of this phenomenon can be found in a study of nonhuman primates showing that boosting with an omicron-specific variant did not result in higher titers of omicron-specific neutralizing antibodies than did boosting with the ancestral strain.<sup>11</sup> This potential problem could limit our ability to respond to a new variant.

It is now incumbent on the CDC to determine who most benefits from booster dosing and to educate the public about the limits of mucosal vaccines. Otherwise, a zero-tolerance strategy for mild or asymptomatic infection, which can be implemented only with frequent booster doses, will continue to mislead the public about what Covid-19 vaccines can and cannot do.

## **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 30 Apr 2022]

*Article*

[No new digest content identified]

## **Pediatrics**

Volume 149, Issue 4, April 1, 2022

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

## **Pharmacoeconomics**

Volume 40, issue 3, March 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-3>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 30 Apr 2022)

[\*\*One step closer to a transmissible vaccine for rabies virus\*\*](#)

Scott L. Nuismer

Primer | published 20 Apr 2022 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3001607>

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 30 Apr 2022)

[No new digest content identified]

**PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 30 Apr 2022)

**Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis**

Benjamin Speich, Dmitry Gryaznov, Jason W. Busse, Viktoria L. Gloy, Szimonetta Lohner, Katharina Klatte, Ala Taji Heravi, Nilabh Ghosh, Hopin Lee, Anita Mansouri, Ioana R. Marian, Ramon Saccilotto, Edris Nury, Benjamin Kasenda, Elena Ojeda-Ruiz, Stefan Schandelmaier, Yuki Tomonaga, Alain Amstutz, Christiane Pauli-Magnus, Karin Bischoff, Katharina Wollmann, Laura Rehner, Joerg J. Meerpohl, Alain Nordmann, Jacqueline Wong, Ngai Chow, Patrick Jiho Hong, Kimberly Mc Cord – De Iaco, Sirintip Sricharoenchai, Arnav Agarwal, Matthias Schwenkglenks, Lars G. Hemkens, Erik von Elm, Bethan Copsey, Alexandra N. Griessbach, Christof Schönenberger, Dominik Mertz, Anette Blümle, Belinda von Niederhäusern, Sally Hopewell, Ayodele Odutayo, Matthias Briel

Research Article | published 27 Apr 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003980>

**Social justice now for an equitable tomorrow: Reflections from the Consortium of Universities for Global Health Conference 2022**

Beryne Odeny, Callam Davidson

Perspective | published 22 Apr 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003995>

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 30 Apr 2022)

[No new digest content identified]

**PLoS One**

<http://www.plosone.org/>

[Accessed 30 Apr 2022]

*Research Article*

**Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods**

Cleo Anastassopoulou, Dimitra Antoni, Yiannis Manoussopoulos, Panagiotis Stefanou, Sofia Argyropoulou, Georgia Vrioni, Athanasios Tsakris

Research Article | published 29 Apr 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0266958>

**Human drone interaction in delivery of medical supplies: A scoping review of experimental studies**

Franziska Stephan, Nicole Reinsperger, Martin Grünthal, Denny Paulicke, Patrick Jahn  
Research Article | published 28 Apr 2022 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0267664>

**Vaccination against misinformation: The inoculation technique reduces the continued influence effect**

Mikołaj Buczel, Paulina D. Szyszka, Adam Siwiak, Małwina Szpitalak, Romuald Polczyk  
Research Article | published 28 Apr 2022 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0267463>

**Responsiveness of open innovation to COVID-19 pandemic: The case of data for good**

Francesco Scotti, Francesco Pierri, Giovanni Bonaccorsi, Andrea Flori  
Research Article | published 26 Apr 2022 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0267100>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 30 Apr 2022]  
[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**

April 26, 2022 vol. 119 no. 17  
<https://www.pnas.org/toc/pnas/119/17>  
[New issue; No digest content identified]

April 19, 2022 | vol. 119 | no. 16  
<https://www.pnas.org/toc/pnas/119/16>  
[New issue; No digest content identified]

**Prehospital & Disaster Medicine**

Volume 37 - Issue 2 - April 2022  
<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>  
[Reviewed earlier]

**Preventive Medicine**

Volume 157 April 2022  
<https://www.sciencedirect.com/journal/preventive-medicine/vol/157/suppl/C>  
[Reviewed earlier]

**Proceedings of the Royal Society B**

13 April 2022 Volume 289 Issue 1972

<https://royalsocietypublishing.org/toc/rspb/current>  
[Reviewed earlier]

### **Public Health**

Volume 205 Pages e1-e30, 1-216 (April 2022)  
<https://www.sciencedirect.com/journal/public-health/vol/205/suppl/C>  
[Reviewed earlier]

### **Public Health Ethics**

Volume 14, Issue 3, November 2021  
<http://phe.oxfordjournals.org/content/current>  
[Reviewed earlier]

### **Public Health Reports**

Volume 137 Issue 2, March/April 2022  
<https://journals.sagepub.com/toc/phrg/137/2>  
[Reviewed earlier]

### **Qualitative Health Research**

Volume 32 Issue 4, March 2022  
<https://journals.sagepub.com/toc/qhra/current>  
[Reviewed earlier]

### **Research Ethics**

Volume 18 Issue 2, April 2022  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 30 Apr 2022]  
[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**  
<https://www.paho.org/journal/en>  
*Selected Articles*  
[No new digest content identified]

### **Risk Analysis**

Volume 42, Issue 3 Pages: 429-655 March 2022  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[Accessed 30 Apr 2022]

*Commentary*

### **Vaccine Inequity and Hesitancy: A Vicious Cycle Undermining the Fight Against the COVID-19 Pandemic**

Gudina EK, Mekonnen Z, Yilma D  
*Risk Management and Healthcare Policy* 2022, 15:865-869  
Published Date: 29 April 2022

*Original Research*

### **Chinese University Students' Awareness and Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study**

Li S, Gao Z, Zhong M, Yu Z, Li J, Bi H  
*Risk Management and Healthcare Policy* 2022, 15:845-864  
Published Date: 29 April 2022

*Review*

### **COVID-19 in Veterans: A Narrative Review**

Chuang YC, Tsai HW, Liu SA, Wu MJ, Liu PY  
*Risk Management and Healthcare Policy* 2022, 15:805-815  
Published Date: 26 April 2022

## **Science**

Volume 376| Issue 6592| 29 Apr 2022  
<https://www.science.org/toc/science/current>

*Policy Forum*

### **A global system for the next generation of vaccines**

BY Nimalan Arinaminpathy, Chadi M. Saad-Roy, Qiqi Yang, Isa Ahmad, Prashant Yadav, Bryan Grenfell  
28 Apr 2022: 462-464

*FULL ACCESS*

*COVID-19 has shown that hurdles can be overcome*

The rapid development of vaccines against COVID-19 raises questions about what could be achieved in vaccines to other major diseases. Influenza presents an important case study; it is one of the few infections that causes substantial public health burden in its endemic form while also having proven pandemic potential. We offer a first step in bringing together the value proposition of future influenza vaccines considering two key characteristics: the breadth of protection that vaccines offer (against individual strains, all strains within a subtype, multiple subtypes, or all subtypes) and the duration for which protection remains effective (see the figure). We examine implications of these characteristics, from both epidemiologic and economic perspectives, and discuss how a future market for influenza vaccines might best align public health and economic incentives. Although many of these factors are

specific to influenza, we consider comparisons with other major infections, such as tuberculosis and COVID-19.

### **Science and Engineering Ethics**

Volume 28, issue 2, April 2022

<https://link.springer.com/journal/11948/volumes-and-issues/28-2>

*Original Research/Scholarship - Open Access*

#### **[Standards of Conducts for Biostatisticians and Stem Cell Researchers: A Call for Self-formulated Aspirational Ethics Over Built-in Prohibitive Ethics](#)**

Keiko Sato & Mika Suzuki

Published: 17 March 2022

##### *Abstract*

We proposed the Standards of Conducts to provide a general framework that will serve as the basis for guiding each biostatistician and stem cell researcher to formulate their personal standards, rather than as rules with which they are required to comply. Given the responsibility and characteristics of their work, they are expected to maintain independence and work autonomously as professionals. Each of the Standards of Conducts comprises a preamble, mission and values to uphold, Standards of Conducts (10 items), and background. When one internalizes "self-formulated" standards, to make excuses for oneself would be akin to a self-betrayal; responsible actions can be anticipated. If one begins and continues to consider "who I am and what do I work for," this will become their inner energy, and a source of motivation and pride to inspire oneself. In addition, this aspirational style might help citizens to recognize the autonomous stance of the professional body and that they share the same values.

### **Science Translational Medicine**

Volume 14| Issue 642| 27 Apr 2022

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 298 April 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/298/suppl/C>

*Research article Open access*

#### **[Vaccine anxieties, vaccine preparedness: Perspectives from Africa in a Covid-19 era](#)**

Melissa Leach, Hayley MacGregor, Grace Akello, Lawrence Babawo, ... Khoudia Sow

Article 114826

*Research article Full text access*

#### **[Applying an extended protection motivation theory to predict Covid-19 vaccination intentions and uptake in 50–64 year olds in the UK](#)**

Bethany Griffin, Mark Conner, Paul Norman

Article 114819

*Research article Abstract only*

#### **[Vaccine discourse in white nationalist online communication: A mixed-methods computational approach](#)**

Dror Walter, Yotam Ophir, Ayse D. Lokmanoglu, Meredith L. Pruden  
Article 114859

*Research article Open access*

**The path towards herd immunity: Predicting COVID-19 vaccination uptake through results from a stated choice study across six continents**

Stephane Hess, Emily Lancsar, Petr Mariel, Jürgen Meyerhoff, ... Mark H.P. Zuidgeest  
Article 114800

*Research article Full text access*

**Inside the 'black box' of COVID-19 vaccination beliefs: Revealing the relative importance of public confidence and news consumption habits**

Jennifer A. Lueck, Timothy Callaghan  
Article 114874

**Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 30 Apr 2022]

**Strategies to overcome vaccine hesitancy: a systematic review**

*Vaccination, albeit a necessity in the prevention of infectious diseases, requires appropriate strategies for addressing vaccine hesitancy at an individual and community level. However, there remains a glaring...*

Authors: Prem Singh, Pritu Dhalaria, Satabdi Kashyap, Gopal Krishna Soni, Partha Nandi, Shreeparna Ghosh, Mrinal Kar Mohapatra, Apurva Rastogi and Divya Prakash

Citation: Systematic Reviews 2022 11:78

Content type: Research Published on: 26 April 2022

**Theoretical Medicine and Bioethics**

Volume 43, issue 1, February 2022

<https://link.springer.com/journal/11017/volumes-and-issues/43-1>

[Reviewed earlier]

**Travel Medicine and Infectious Diseases**

Volume 46 March–April 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/46/suppl/C>

[Reviewed earlier]

**Tropical Medicine & International Health**

Volume 27, Issue 4 Pages: i-iv, 337-465 April 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

*RESEARCH ARTICLES*

**COVID-19 vaccine acceptability among healthcare workers in Ethiopia: Do we practice what we preach?**

Daniel Yilma, Rezika Mohammed, Seid Getahun Abdela, Wendemagegn Enbiale, Fasil Seifu, Myrthe Pareyn, Laurens Liesenborghs, Johan van Griensven, Saskia van Henten

Pages: 418-425

First Published: 01 March 2022

## **Vaccine**

Volume 40, Issue 16 Pages 2365-2472 (6 April 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/16>

*Research article Full text access*

### **Sociodemographic and psychological correlates of COVID-19 vaccine hesitancy and resistance in the young adult population in Italy**

Ughetta Moscardino, Pasquale Musso, Cristiano Inguglia, Chiara Ceccon, ... Cécile Rousseau

Pages 2379-2387

*Research article Open access*

### **Public health facility quality and child immunization outcomes in rural India: A decomposition analysis**

Amit Summan, Arindam Nandi, Emily Schueller, Ramanan Laxminarayan

Pages 2388-2398

*Research article Abstract only*

### **Policy and practice of checking vaccination status at school in 2018, a global overview**

Katrin Sadigh, Garrett Fox, Nino Khetsuriani, Hongjiang Gao, ... Kirsten Ward

Pages 2432-2441

*Research article Full text access*

### **COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France**

Pierre-julien Coulaud, Aidan Ablona, Naseeb Bolduc, Danya Fast, ... Rod Knight

Pages 2442-2456

*Research article Full text access*

### **Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States**

Matthias Klumpp, Ida G. Monfared, Sebastian Vollmer

Pages 2457-2461

## **Value in Health**

April 2022 Volume 25 Issue 4 p473-676

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

::::::

::::::

## **Pre-Print Servers**

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

*No new digest content identified.*

## **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

### **The impact of COVID-19 pandemic on influenza surveillance: a systematic review and meta-analysis**

Sasidharanpillai Sabeena, N Ravishankar, Sudandiradas Robin

medRxiv 2022.03.31.22273236; doi: <https://doi.org/10.1101/2022.03.31.22273236> Revision

### **Higher contact among vaccinated can be a mechanism for negative vaccine effectiveness**

Korrin Bodner, Jesse Knight, Mackenzie A. Hamilton, Sharmistha Mishra

medRxiv 2022.04.25.22274266; doi: <https://doi.org/10.1101/2022.04.25.22274266> Revision

### **Which countries need COVID-19 vaccines the most? Development of a prioritisation tool**

Vageesh Jain, Rifat Atun, Paul Hansen, Paula Lorgelly

medRxiv 2022.04.27.22274377; doi: <https://doi.org/10.1101/2022.04.27.22274377>

### **A systematic review of the experiences of minority language users in health and social care research**

Dr Llinos Haf Spencer, Mrs Beryl Ann Cooledge, Dr Zoe Hoare

medRxiv 2022.04.27.22273307; doi: <https://doi.org/10.1101/2022.04.27.22273307>

### **Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco**

Yaowen Zhang, Jihane Belayachi, Yunkai Yang, Qiang Fu, Lance Rodewald, Hongling Li, Bing Yan, Ying Wang, Yanna Shen, Qian Yang, Weiyun Mu, Rong Tang, Chen Su, Tianfang Xu, Majdouline Obtel, Abdelkader Mhayi, Rachid Razine, Redouane Abouqal, Yuntao Zhang, Xiaoming Yang  
medRxiv 2022.04.23.22274112; doi: <https://doi.org/10.1101/2022.04.23.22274112>

### **Mondo: Unifying diseases for the world, by the world**

Nicole A Vasilevsky, Nicolas A Matentzoglu, Sabrina Toro, Joseph E Flack IV, Harshad Hegde, Deepak R Unni, Gioconda F Alyea, Joanna S Amberger, Larry Babb, James P Balhoff, Taylor I Bingaman, Gully A Burns, Orion J Buske, Tiffany J Callahan, Leigh C Carmody, Paula Carrio Cordo, Lauren E Chan, George S Chang, Sean L Christiaens, Michel Dumontier, Laura E Failla, May J Flowers, H. Alpha Garrett Jr., Jennifer L Goldstein, Dylan Gration, Tudor Groza, Marc Hanauer, Nomi L Harris, Jason A Hilton, Daniel S Himmelstein, Charles Tapley Hoyt, Megan S Kane, Sebastian Köhler, David Lagorce, Abbe Lai, Martin Larralde, Antonia Lock, Irene López Santiago, Donna R Maglott, Adriana J Malheiro, Birgit H M Meldal,

Monica C Munoz-Torres, Tristan H Nelson, Frank W Nicholas, David Ochoa, Daniel P Olson, Tudor I Oprea, David Osumi-Sutherland, Helen Parkinson, Zoë May Pendlington, Ana Rath, Heidi L Rehm, Lyubov Remennik, Erin R Riggs, Paola Roncaglia, Justyne E Ross, Marion F Shadbolt, Kent A Shefchek, Morgan N Similuk, Nicholas Sioutos, Damian Smedley, Rachel Sparks, Ray Stefancsik, Ralf Stephan, Andrea L Storm, Doron Stupp, Gregory S Stupp, Jagadish Chandrabose Sundaramurthi, Imke Tammen, Darin Tay, Courtney L Thaxton, Eloise Valasek, Jordi Valls-Margarit, Alex H Wagner, Danielle Welter, Patricia L Whetzel, Lori L Whiteman, Valerie Wood, Colleen H Xu, Andreas Zankl, Xingmin Aaron Zhang, Christopher G Chute, Peter N Robinson, Christopher J Mungall, Ada Hamosh, Melissa A Haendel  
medRxiv 2022.04.13.22273750; doi: <https://doi.org/10.1101/2022.04.13.22273750> **Revision**

### **Strengthening vaccination delivery system resilience in the context of protracted humanitarian crisis: a realist-informed systematic review**

Sharif A. Ismail, Sze Tung Lam, Sadie Bell, Fouad M. Fouad, Karl Blanchet, Josephine Borghi  
medRxiv 2022.04.21.22273340; doi: <https://doi.org/10.1101/2022.04.21.22273340> Revision

**Wellcome Open Research** [to 30 Apr 2022]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 30 Apr 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

*Research Article* metrics

Revised

**What are the active ingredients of 'arts in health' activities? Development of the INgredients IN ArTs in hEalth (INNATE) Framework** [version 2; peer review: 1 approved, 1

approved with reservations]

Katey Warran, Alexandra Burton, Daisy Fancourt

Peer Reviewers Gunter Kreutz; Melissa Forbes

Funders

Wellcome Trust

Leverhulme Trust

UK Research and Innovation

LATEST VERSION PUBLISHED 29 Apr 2022

\*

\*

\*

\*

### **Think Tanks**

**Brookings** [to 30 Apr 2022]

<http://www.brookings.edu/>

Accessed 30 Apr 2022

*Latest Research*

*Essay*

**Lessons learned from support to business during COVID-19**

Gabriel Chodorow-Reich, Ben Iverson, and Adi Sunderam  
Wednesday, April 27, 2022

*Essay*

**Lessons learned from expanded unemployment insurance during COVID-19**

Peter Ganong, Fiona Greig, Pascal Noel, Daniel M. Sullivan, and Joseph Vavra  
Wednesday, April 27, 2022

*Essay*

**Lessons learned from the use of nontraditional data during COVID-19**

Tomaz Cajner, Laura J. Feiveson, Christopher J. Kurz, and Stacey Tevlin  
Wednesday, April 27, 2022

*Essay*

**Lessons learned from support for the state and local sector during COVID-19**

Louise Sheiner  
Wednesday, April 27, 2022

*Essay*

**Lessons learned from the COVID-19 policy response and child well-being**

Anna Aizer and Claudia Persico  
Wednesday, April 27, 2022

**Center for Global Development** [to 30 Apr 2022]

<https://www.cgdev.org/>

*Research [Selected]*

*BRIEFS*

**ABCs of the IFIs: Understanding IDA20**

Jocilyn Estes and Erin Collinson  
April 29, 2022

With the COVID-19 pandemic hitting government balance sheets especially hard in low-income countries, the World Bank's shareholders—including the United States—agreed to an advance replenishment of its grant and low-interest loan window, the International Development Association (IDA). By holding a ...

*BRIEFS*

**Understanding the Cost-Effectiveness of COVID-19 Vaccination in Nigeria**

Benjamin S.C. Uzochukwu et al.  
April 28, 2022

COVID-19 has disrupted health systems across the globe. Nigeria reported its first COVID-19 case in February 2020, and, since then, the government has rolled out four vaccines to help control the pandemic—Moderna, Oxford-Astra Zeneca (AZ), Johnson & Johnson (J&J) and Pfizer-BioNTech.

*BRIEFS*

**Understanding the Cost-Effectiveness of COVID-19 Vaccination in Ethiopia**

Anthony McDonnell et al.  
April 28, 2022

COVID-19 radically changed most people's lives in 2020, including across Africa. In Ethiopia, the disruption started with school closing, and other restrictions soon followed. Despite these efforts to contain the virus, Ethiopia—like almost all countries—suffered significant health impacts. It has r...

**Chatham House** [to 30 Apr 2022]

<https://www.chathamhouse.org/>

Accessed 30 Apr 2022

[No new digest content identified]

**CSIS** [to 30 Apr 2022]

<https://www.csis.org/>

Accessed 30 Apr 2022

Transcript

[\*\*Equity in Immunization Services to Ensure "A Long Life for All"\*\*](#)

April 29, 2022

*Podcast Episode*

[\*\*Covid, Ukraine, and the New Geopolitical Logic\*\*](#)

April 28, 2022 | By [H. Andrew Schwartz](#), [J. Stephen Morrison](#)

*Report*

[\*\*Securing Medical Supply Chains with Trusted Trade Partners\*\*](#)

April 29, 2022 | [Meredith Broadbent](#) A new report from CSIS assesses the potential of nearshoring medical supply chains to neighbors in the Americas, using the case studies of Canada, Brazil, Mexico, and Colombia.

**Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

Accessed 30 Apr 2022

Accessed 30 Apr 2022

[No new digest content identified]

**ODI [Overseas Development Institute]** [to 30 Apr 2022]

<https://odi.org/en/publications/>

*Publications*

Accessed 30 Apr 2022

[No new digest content identified]

**Rand** [to 30 Apr 2022]

<https://www.rand.org/pubs.html>

*Reports, Selected Journal Articles*

*Report*

## **A Risk Assessment of National Critical Functions During COVID-19: Challenges and Opportunities**

This report presents a framework for assessing risk that the coronavirus disease 2019 (COVID-19) poses to the National Critical Functions, describes challenges in implementing the framework, and provides recommendations for improving it.

Apr 26, 2022

Andrew Lauland, Benjamin Lee Preston, Kristin J. Leuschner, Michelle E. Miro, Liam Regan, Scott R. Stephenson, Rachel Steratore, Aaron Strong, Jonathan W. Welburn, Jeffrey B. Wenger

**Urban Institute** [to 30 Apr 2022]

<https://www.urban.org/publications>

*Research Publications*

*Brief*

**[COVID-19 and the System Resilience of Public Education: A View from North Carolina](#)**

April 28, 2022

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#))/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

*Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

:::::::

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*